PH27036A - Process for the preparation of diol containing renin inhibitors - Google Patents
Process for the preparation of diol containing renin inhibitors Download PDFInfo
- Publication number
- PH27036A PH27036A PH40714A PH40714A PH27036A PH 27036 A PH27036 A PH 27036A PH 40714 A PH40714 A PH 40714A PH 40714 A PH40714 A PH 40714A PH 27036 A PH27036 A PH 27036A
- Authority
- PH
- Philippines
- Prior art keywords
- nhch
- cad
- phe
- mmole
- solution
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 26
- 238000002360 preparation method Methods 0.000 title claims description 17
- 239000002461 renin inhibitor Substances 0.000 title description 4
- 229940086526 renin-inhibitors Drugs 0.000 title description 4
- 150000002009 diols Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims description 69
- 150000001875 compounds Chemical class 0.000 claims description 56
- 229920006395 saturated elastomer Polymers 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 20
- 239000002253 acid Substances 0.000 claims description 18
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
- 101000864324 Boswellia serrata Basic secretory protease Proteins 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims description 4
- 150000004702 methyl esters Chemical class 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 150000003141 primary amines Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 173
- 239000000243 solution Substances 0.000 description 115
- 239000000047 product Substances 0.000 description 94
- 239000002904 solvent Substances 0.000 description 92
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 89
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 85
- 235000019439 ethyl acetate Nutrition 0.000 description 84
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 83
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 78
- 239000000203 mixture Substances 0.000 description 77
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 69
- 238000005481 NMR spectroscopy Methods 0.000 description 65
- 238000004949 mass spectrometry Methods 0.000 description 56
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 52
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- 239000000741 silica gel Substances 0.000 description 47
- 229910002027 silica gel Inorganic materials 0.000 description 47
- 238000001035 drying Methods 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- 239000007787 solid Substances 0.000 description 40
- 238000004587 chromatography analysis Methods 0.000 description 37
- 239000012043 crude product Substances 0.000 description 37
- -1 (l-naphthyl)methyl Chemical group 0.000 description 36
- 238000006243 chemical reaction Methods 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 239000006260 foam Substances 0.000 description 31
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 238000003756 stirring Methods 0.000 description 30
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 23
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- 239000000725 suspension Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 108090000783 Renin Proteins 0.000 description 15
- 102100028255 Renin Human genes 0.000 description 15
- 239000000543 intermediate Substances 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 11
- 239000010410 layer Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 150000002431 hydrogen Chemical class 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 125000006414 CCl Chemical group ClC* 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229910002091 carbon monoxide Inorganic materials 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- 206010020571 Hyperaldosteronism Diseases 0.000 description 7
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 7
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 7
- 230000008878 coupling Effects 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 206010019280 Heart failures Diseases 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 description 5
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 5
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 5
- 239000012285 osmium tetroxide Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000004611 spectroscopical analysis Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000001665 trituration Methods 0.000 description 5
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 4
- 101150065749 Churc1 gene Proteins 0.000 description 4
- 102100038239 Protein Churchill Human genes 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 3
- DQUHYEDEGRNAFO-QMMMGPOBSA-N (2s)-6-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCCN DQUHYEDEGRNAFO-QMMMGPOBSA-N 0.000 description 3
- QDOUGIFZJJVBOL-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]propanedioic acid Chemical compound CC(C)(C)OC(=O)NC(C(O)=O)C(O)=O QDOUGIFZJJVBOL-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 101800000734 Angiotensin-1 Proteins 0.000 description 3
- 102400000344 Angiotensin-1 Human genes 0.000 description 3
- 102000004881 Angiotensinogen Human genes 0.000 description 3
- 108090001067 Angiotensinogen Proteins 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 2
- IDWHSUSIOBKSKI-UHFFFAOYSA-N 2-[cyclohexyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)N(CC(O)=O)C1CCCCC1 IDWHSUSIOBKSKI-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- 241000735552 Erythroxylum Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 2
- 101100220369 Mus musculus Csgalnact1 gene Proteins 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000008957 cocaer Nutrition 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 238000010265 fast atom bombardment Methods 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- AXEVAAYUGSXTBP-UHFFFAOYSA-N n-morpholin-4-ylsulfamoyl chloride Chemical compound ClS(=O)(=O)NN1CCOCC1 AXEVAAYUGSXTBP-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- AALYNABLSOHPQK-BYPYZUCNSA-N (2s)-2-(1,3-thiazol-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CSC=N1 AALYNABLSOHPQK-BYPYZUCNSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- WAMWSIDTKSNDCU-ZETCQYMHSA-N (2s)-2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)[C@@H](N)C1CCCCC1 WAMWSIDTKSNDCU-ZETCQYMHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- KPWDGTGXUYRARH-UHFFFAOYSA-N 2,2,2-trichloroethanol Chemical compound OCC(Cl)(Cl)Cl KPWDGTGXUYRARH-UHFFFAOYSA-N 0.000 description 1
- ULIKDJVNUXNQHS-UHFFFAOYSA-N 2-Propene-1-thiol Chemical compound SCC=C ULIKDJVNUXNQHS-UHFFFAOYSA-N 0.000 description 1
- KIAPYAZGXJCKQL-UHFFFAOYSA-N 2-[n-[(2-methylpropan-2-yl)oxycarbonyl]anilino]acetic acid Chemical compound CC(C)(C)OC(=O)N(CC(O)=O)C1=CC=CC=C1 KIAPYAZGXJCKQL-UHFFFAOYSA-N 0.000 description 1
- SYAWIBYLGMIDLB-UHFFFAOYSA-N 2-amino-2-methoxycarbonyl-3-[(2-methylpropan-2-yl)oxy]-3-oxopropanoic acid Chemical compound COC(C(C(=O)O)(N)C(=O)OC(C)(C)C)=O SYAWIBYLGMIDLB-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- WWYDYZMNFQIYPT-UHFFFAOYSA-L 2-phenylpropanedioate Chemical compound [O-]C(=O)C(C([O-])=O)C1=CC=CC=C1 WWYDYZMNFQIYPT-UHFFFAOYSA-L 0.000 description 1
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
- LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
- LBXKQIWKQYEXRO-UHFFFAOYSA-N 3-methylbutanoyl bromide Chemical compound CC(C)CC(Br)=O LBXKQIWKQYEXRO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- FZDKHFNKZOXGAZ-UHFFFAOYSA-N 6-methylheptane-3,4-diol Chemical compound CCC(O)C(O)CC(C)C FZDKHFNKZOXGAZ-UHFFFAOYSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100031186 Chromogranin-A Human genes 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 101000993094 Homo sapiens Chromogranin-A Proteins 0.000 description 1
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- VIHYIVKEECZGOU-UHFFFAOYSA-N N-acetylimidazole Chemical compound CC(=O)N1C=CN=C1 VIHYIVKEECZGOU-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- GEYBMYRBIABFTA-VIFPVBQESA-N O-methyl-L-tyrosine Chemical compound COC1=CC=C(C[C@H](N)C(O)=O)C=C1 GEYBMYRBIABFTA-VIFPVBQESA-N 0.000 description 1
- FADYJNXDPBKVCA-STQMWFEESA-N Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 FADYJNXDPBKVCA-STQMWFEESA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229910019567 Re Re Inorganic materials 0.000 description 1
- 101100046503 Symbiobacterium thermophilum (strain T / IAM 14863) tnaA1 gene Proteins 0.000 description 1
- SWEDAZLCYJDAGW-UHFFFAOYSA-N Thiophene-2-thiol Chemical compound SC1=CC=CS1 SWEDAZLCYJDAGW-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- ORWKVZNEPHTCQE-UHFFFAOYSA-N acetic formic anhydride Chemical compound CC(=O)OC=O ORWKVZNEPHTCQE-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- LCIPKAVMAXVOTJ-UHFFFAOYSA-N benzyl 4-(chlorosulfonylamino)piperazine-1-carboxylate Chemical compound C1CN(NS(=O)(=O)Cl)CCN1C(=O)OCC1=CC=CC=C1 LCIPKAVMAXVOTJ-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000012062 charged aerosol detection Methods 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011960 computer-aided design Methods 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000000911 decarboxylating effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GLFVNTDRBTZJIY-UHFFFAOYSA-N diethyl 2-aminopropanedioate;hydron;chloride Chemical compound Cl.CCOC(=O)C(N)C(=O)OCC GLFVNTDRBTZJIY-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000006277 halobenzyl group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- NIWYLNFSJJLYHU-UHFFFAOYSA-N n-ethyl-1-(2-fluorophenyl)propan-2-amine Chemical compound CCNC(C)CC1=CC=CC=C1F NIWYLNFSJJLYHU-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OFYAYGJCPXRNBL-LBPRGKRZSA-N naphthalen-2-yl-3-alanine Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-LBPRGKRZSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 238000000675 plasmon resonance energy transfer Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008259 solid foam Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- OSMRWYUPMDKOMI-UHFFFAOYSA-N tert-butyl n-cyclohexyl-n-(2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)N(CC=O)C1CCCCC1 OSMRWYUPMDKOMI-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical class C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical class C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Description
ol
DIOL-CONTAINING RENIN INHIBITORS )
This is a divisional application of application Serial No. 38698 filed on May 25, 1989.
Renin is a natural enzyme which is released into the blood from the kidney. It cleaves its natural substrate, ) 5 angiotensinogen, releasing decapeptide, angiotensin I. This ra is in turn cleaved by converting enzyme in the lung, kidney and other tissues to an octapeptide, angiotensin II.
Angiotensin II raises blood pressure both directly by causing arteriolar constriction and indirectly by stimulating release of the sodium-retaining hormone aldosterone from the adrenal - gland causing a rise in extracellular fluid volume. co
Inhibitors of renins have been sought as agents for control ’ of hypertension, congestive heart failure, and hyperaldosteronism.
European Application No. 86,/106458 covers certain renin- inhibiting N-(acyldipeptidyl)-aminoglycols of the formula
Co Cg mo®9 2s
Cc Cc N Cc Co CH
JN/N\/\ /N\/ amen
C20 R, N c ¢ N ! OH
H 0 Rj , wherein R,; is alkoxy containing one to six carbon atoms or lower alkyl containing one to six carbon atoms; Rp is benzyl or napthylmethyl, Rs is lower alkyl containing one to six carbon atoms or imidazolemethyl; Ry is benzyl, Rs is hydrogen or lower alkyl and n is O. These compounds are useful as . renin inhibitors. :
, 5 -2 =- 1
European Application No. 87/100424 covers renin inhibiting peptidyl-amino-diols of formula
Rj; H Rg
A ow P. N Rg : : NTT I
Ry oO Ry Rg Ry
R, wherein A is a substitutent; W is C=0 or CHOH; U is CH, or
NR,; R; is lower alkyl, cycloalkylmethyl, benzyl, 4-methoxybenzyl, halobenzyl, (l-naphthyl)methyl, : (2-naphthyl)methyl, (4-imidazoyl)methyl, a,a-dimethylbenzyl, - 1-benzyloxyethyl, phenethyl, phenoxy, thiophenoxy or anilino;
R; is lower alkyl, [(alkoxy)alkoxylalkyl, (thioalkoxy)alkyl, lower alkenyl, benzyl or heterocyclic ring substituted — 15 methyl; Ry is lower alkyl, cycloalkylmethyl or benzyl; Rs is vinyl, formyl, hydroxymethyl or hydrogen; R; is hydrogen or lower alkyl; Rg and Rg are independently selected from OH and
NH,; and Rg is hydrogen, lower alkyl, vinyl or arylalkyl.
Structurally the positions of the various amino acids of the compounds of the instant invention may be designated by reference to the octapeptide which is the minimal : angiotensinogen sequence cleaved by renin, namely:
HIS® — PRO’ — PHES — HIS® — LEU! 0— VAL!! —VAL!2 — TYR!3 ! 1 " scissile bond © : Lo 25 Py — Py — P3 — Py — P; ——P;' — P,' — P3' ‘ A designation for the compounds of this invention is illustrated below. The CAD is considered to occupy the
P,-P,' positions. For example : ani 0 N-S-PHE-NHCH( CO, CH4 )CO-CAD ~/ .
Rod IE
Py—P3 Pp — Py-P,'
oo -3-
The present invention concerns novel peptides which inhibit renin. It also concerns pharmaceutical compositions containing these novel peptides, methods of treating renin- associated hypertension, congestive heart failure, and hyperaldosteronism, as well as the use of the peptides as diagnostic tools, and the methods for preparing the peptides.
Since HIV protease, like renin, is an aspartyl protease, these compounds can also be used to treat diseases caused by retroviruses including HTLV-II and -III. ’ 10 SUMMARY OF THE INVENTION } A
The present invention relates to novel peptides of the formula
A-X~Y-W (1) : and the pharmaceutically acceptable acid addition salts thereof wherein A, X, Y, W are as defined herein below. . The invention also includes pharmaceutical compositions ! comprising an effective amount of the above peptide of formula I in admixture with a pharmaceutically acceptable carrier or excipient and a method for treating renin-associated hypertension in a patient suffering therefrom comprising administering to said patient the above pharmaceutical composition in unit dosage form.
Further the invention includes a pharmaceutical ~ composition comprising an effective amount of a peptide of formula I above in admixture with a pharmaceutically acceptable carrier or excipient, and a method for treating hyperaldosteronism in a patient suffering therefrom comprising administering to said patient the above pharmaceutical composition in unit dosage form.
Further the invention includes a pharmaceutical composition comprising an effective amount of a peptide of : formula I in admixture with a pharmaceutically acceptable carrier or excipient, and a method for treating congestive oo 23 7 - 4 - ’ heart failure in a patient suffering therefrom comprising administering to said patient the above pharmaceutical composition in unit dosage form.
The present invention also includes the use of peptides of formula I above as diagnostic tools for the identification of cases of hypertension due to renin excess.
The present invention also includes the use of peptides of formula I to treat diseases caused by retroviruses.
The invention further includes methods for preparing peptides of formula I above.
The following table provides a dictionary of the terms used in the description of the invention. he TABLE 1
Abbreviated ] Designation Amino Acid
PHE L-Phenylalanine
HOMOPHE Homophenylalanine
LYS L~Lysine
NAPHTHYLALA l1-Naphthylalanine
CYCLOHEXYLALA Cyclohexylalanine
TYR(OMe) O-Methyl-L-tyrosine ~~ TYR L-Tyrosine
TZA 4-Thiazolylalanine
HIS L-Histidine
ASN L-Asparagine
C-Terminal Group
CAD _ -HNCHCH(OH)CH(OH) CH, CH(CHj ) ,
Are ) Ce
TABLE I (Continued)
Abbreviated
Designated C-Terminal Group
CAH ~NHCHCH (OH) CH (OH )CH, CH(CH3 ), e
Protecting Group z Benzyloxycarbonyl
BOC Tert-butyloxycarbonyl
TRT Triphenylmethyl
Acyls iva Isovaleryl
BNMA Bis-(1l-naphthylmethyl)acetyl
BBSP 2-Benzyl-3-(t-butylsulfonyl) : propionyl : Z2-BMA 3-(Benzyloxycarbonylamino)-3- methylbutanoyl
BMA 3-Amino-3-methylbutanoyl - Esters With -0CHj3 Methanol -0C, Hg Ethanol -OCH(CHj3), 2-Prcpanol ~0C(CH;3 )3 tert-Butanol
Solvents and Reagents
CHCl, Chloroform
DMF N,N-Dimethyl formamide
Ofe3t - i . - 6 =
TABLE I (Continued)
Abbreviated
Designated Solvents and Reagents
DMSO Dimethylsul foxide
HOBT Hydroxybenzotriazole
DCC N,N'-Dicyclohexylcarbodiimide
HOAC Acetic acid
EtsN Triethylamine
THF Tetrahydrofuran
CH, Cl, Dichloromethane : MeOH Methanol
EtOAc Ethyl acetate
The peptides of the present invention are represented by
CT the formula
A-X-Y-W 1 or a pharmaceutically acceptable acid addition salt thereof, wherein
R 0 __. 0 . No RL
Co A.is BOC, IVA, NVA, BNMA, BMA, BBSP, 2, Pat , 9 N-5= ’
R'" 0 -7 0 0 ®@ Q
CH a \ n n
Ole) 3 N—§— (CH3) sNCH,CHN=S— / noo LN ¢ cH \— § g® R"O wherein G is hydroxyl or halide, ya
270%¢ . -7 - oo 7 wherein D is -N 0, / -~ |, a
CO, CH ze 2CHgj
D ~NCH, CO, CHg ,
CH, -OCHj,
I's -N >, or -N(CHj; )2 r wherein R and R' are each independently hydrogen, straight . or branched chain lower alkyl, or R and R' are P-CH,CHj, oe wherein P can be OR", SR", NR"R"' or NR"COR" wherein R" and
R"' can be hydrogen, or straight or branched chain lower alkyl, or P is NR"R"' where it forms a heterocyclic ring containing from 4 to 6 carbon atoms or containing one or more
Ton : oo atoms selected from S, O, or NR". Q N is a saturated ring ~ / containing 1 to 5 carbon atoms wherein Q is CHp, 0, S, or NR;
X is absent, PHE, HOMOPHE, NAPHTHYLALA, CYCLOHEXYLALA,
TYR, or TYR(OMe) with the proviso that when A is BNMA, BBSP, or + } *
2 o3(s \ f = . - 8 - : ) ’ < -
D
X is absent; :
Y is GLY, -N—=CH-CO- ’ -N——CH-CO- , -N—CH-CO-~ ' t
Ria SR, Ry4 SO-Ry Riq(CHz)p)
NHR, -N—CH-CO- , ~N—CH-CO- ,
BL CH, -C=C-CH, NHR, Rig CH, CH=CHCH; NHR, -N——CH~-CO-, -N—CH-CO-,
R;4 OR, R,4 CH,CN : ~N—CH~-CO-, ~N-—CH-CO-, or
Ry4 NHR7 Ry4 CO2Ry2 ~N—-~CHCO-
Ria N
R7; Rg wherein R, is lower alkyl, alkenyl, alkynyl, aryl, ” heteroaryl, aralkyl, (CHz )~NHR,, wherein n is an integer of from 2 to 4, and R; is
G-NHCH3, C-NHCH; , G-NHNO, , C-SCHj , C-NHCHj,
Oo S NH NCN NCN
C-Rg, -C~CHNHRs , CCH, CH, NHC-Rs , wherein R; is hydrogen, : 0 0 Ry 0 0 lower alkyl, or aryl, Rs is H, lower alkyl or aralkyl,
Rg is -NHCHg, C-NHCH; , C-NHNO , C-SCH; , C-NHCH3 G-Re 0 S NH NCN NCN 0 wherein Rg is hydrogen, lower alkyl or aryl, :
Lo gol 7 -9 - wherein R; is Ry, C-NHCHs, C-NHCH , C-NHNO2 C-SCHa G-NHCHa , 0 S NH NCN NCN
CRs, C-ORo C-CH-NHR; , C-CH, CH, NER, H, 1 0 0 0 R4 0 wherein R;; is hydrogen, lower alkyl, alkenyl, alkynyl, ’ R
Ris aralkyl, or (CHz2 YN
Ry3 wherein Rg is lower alkyl or together with Rg, when R; is _ 10 lower alkyl, forms a heterocyclic ring containing from 4 to 6 re carbon atoms optionally containing one or more Ss, 0, or NR;
Rg is alkyl or aralkyl; Rys is H or lower alkyl; Ry4 is H or
CH;, and Y is also HIS or TZA with the proviso that when Y is
HIS or T2A, A is BBSP;
W is - OH
NH Ri
Rio OH } where Ryo is lower alkyl, cycloalkyl, cycloalkylmethyl or benzyl and Ry; is lower alkyl. preferred compounds of the present invention are those
Co of formula I wherein A is BOC, BNMA, BBSP, BMA,
R__ 0
N-S- , “ Sn
R' 0 .. © ’ vi
Q N-S- , or ~_ 7 il
~\ wherein D is -N 0 ; 2 and °°
D
X is absent, PHE, NAPHTHYLALA, TYR(OMe) with the proviso that when A is BNMA, BBSP, or
X is absent ;
C
<<
D
Y is ~NH-CH-CO-, -NH-CH-CO-, -NHCH-CO-, -NHCHCO-, } oo SR, (CHz ) OR; CH,CN
NHR, -NHCHCO-, or -NHCH-CO-; and
CH, © COzRy2
RQ C=C-CH; NHR,
OH
Ww is -NH Ry; where R is cycloalkyl or ~~ 11 10 Y Y
R,, OH cycloalkylmethyl.
More preferred compounds of the present invention are those of formula I wherein Y is ~NH-CH-CO- wherein Ry, is ’ CO2R;2 hydrogen, or lower alkyl.
commana mn et a — Te —————— 9902" - 11 -
Other more preferred compounds of the present invention are those of formula I wherein Y 1s ~-NH-CH-CO- or
SR
-NH-CH-CO- wherein Ry, is lower alkyl, alkenyl, or alkynyl.
OR,
Other more preferred compounds of the present invention A are those of formula I wherein Y is -NH-CH-CO- wherein Rp 1s : (CHz)4
NHR, ~C-NHCH, , ~C-NHNO , ~C-SCHy , ~C-NHCH, or -C-Ra.
S NH NCN 0 0
Other more preferred compounds of the present invention are those of formula I wherein Y is =-NHCHCO- wherein . CH, C=C-CH, NHR,
Rg is ~G-Rs- 6° ~~ other more preferred compounds of the present invention are those of formula 1 wherein Y is ~NHCHCO-
CH, CN still other preferred compounds of the present invention are those of formula I wherein A is 0 Cs ~~ p—— 0 N-5-, N-S-, CHaN_ N-8-, or HN N-8-
Co O CH © 0 0 and X is PHE, NAPHTHYLALA or TYR(OMe) . still other preferred compounds of the present invention are those of formula I wherein W is oH -NH Sc
Rio OH wherein R,, is cyclohexyl or cyclohexylmethyl.
Particularly preferred compounds falling within the scope of the invention include the following compounds, their isomers, and pharmaceutically acceptable acid addition salts.
PS wd
BOC-PHE-NHCH (CO, CH; )CO-CAD,
BMA-PHE-NHCH (CO, CH; JCO-CAD, 0 1 : * HN N-S-NAPHTHYLALA-NHCH(COz Cls JCOCAD, 0 0
Nh
CH3N N-S-NAPHTHYLALA-NHCH (CO, CH, ) CO=CAD. : 0
CHa 9 > N-S-NAPHTHYLALA-NHCH(CO2 CH; ) CO-CAD, \
CH; 0
RBOC-NAPHTHYLALA-NHCH (CO, CH3 )CO-CAD,
IVA-NAPHTHYLALA~-NHCH (CO, CH3 )CO-CAD,
BMA-NAPHTHYLALA-NHCH (CO, CH3 )CO-CAD, 0
NN i
HN N-S-TYR (OMe )-NHCH( CO, CH3 ) CO-CAD, ! ws 0 0
Nl)
CH3N N-S-TYR(OMe) -NHCH( CO Cig } CO-CAD.
Ns . 20 0
BOC-TYR (OMe ) ~NHCH( CO, CH3 )CO-CAD,
IVA-TYR (OMe ) -NHCH( CO, CH3 }CO-CAD,
BMA-TYR (OMe ) -NHCH( CO, CH3 )CO-CAD, : 0 . SNH oN N-S-PHE-NHCH(CO, Et) CO-CAD, 7 0 . 0 ; ! NN " ee HN N-S-PHE-NHCH(CO3Et)CO-CAD,
Ne I 0 0
Nh
CHa N N-S-PHE-NHCH(CO,Et)CO-CAD, wy I 0
CH; 0 ~ I _ N-§-PHE-NHCH(CO, Et) CO-CAD. " CHj 0 . ’ BOC-PHE-NHCH(CO,Et)CO-CAD,
: fer : : : . - 13 - 1VA-PHE-NHCH (CO,Et ) CO-CAD, . BMA-PHE-NHCH (CO4Et ) CO-CAD, ° .
ER
0 N-S-NAPHTHYLALA-NHCH (COZ BE) COTCADY
Nod 0 0 [BE I
HN N-S-NAPHTHYLALA-NHCH (CO,Et)CO-CAD,
NN... 0 - "0 0 [
CH;N N-S-NAPHTHYLALA-NHCH( CO,Et) COmCAD,
Na. 7 0
CH,4 0 . ~_
N-S-NAPHTHYLALA-NHCH(CO,E¢) COTERDY
CH, 0
BOC-NAPHTHYLALA-NHCH (CO,Et)CO-CAD,
Tt IVA-NAPHTHYLALA-NHCH (CO,Et)CO-CAD,
BMA-NAPHTHYLALA-NHCH (CO,Et )CO-CAD, 0 ronaN . HN N-S-TYR (OMe ) ~NHCH (CO, Et) CO~CAD, ~~ / 0 0
FN I
0 N-5-TYR (OMe) -NHCH (CO, Et)CO-CAD,
A I
. Oo -. o sw hW . 25 CH;3N N-S-TYR (OMe) ~NHCH(CO,EE) COCA,
Ne 0
LL. - CH, Oo ~N dl __N--TYR(OMe) -NHCH(CO,EL) COmCRD: . CHa 0 .
BOC-TYR (OMe ) -NHCH (CO,Et ) CO-CAD,
IVA-TYR (OMe) -NHCH (CO, Et )CO-CAD,
BMA-TYR (OMe ) -NHCH (CO,Et ) CO-CAD, 0 i
Nn
HN N-§-PHE-NHCH(COp=1-Pr) COCR, oo { °
A . Sn - So TT Re ————— ee —
He : - 14 - 0 an I
CH,N N-S-PHE-NHCH(CO,~1-Pr) COZCAD nf 0
CH, 0 ~.
N-§-PHE-NHCH (CO, iPr) COZCAD: cus” 0
BOC-PHE-NHCH (CO,-i-Pr)CO-CAD, - IVA-PHE-NHCH (CO, -i-Pr)CO-CAD,
BMA-PHE-NHCH (CO,—-1i-Pr )CO-CAD, 0 . ~— 0 N-S-NAPHTHYLALA-NHCH (CO,-i-Pr)CO-CAD, / 1] 0 0 . ~~ ]
HN N-§-NAPHTHYLALA-NHCH COp=1-Pr) COZCADy \—/ 0 - 0 ~~ 1}
CHaN N-§-NAPHTHYLALA-NHCH (CO, ~1-Pr) COCR: rt 0 . CHa _ 9 N-S-NAPHTHYLALA-NHCH(CO,™ Pr) COTCRDY
CH, 0
BOC-NAPHTHYLALA-NHCH (CO,-1-Pr)CO-CAD, a , : IVA-NAPHTHYLALA-NHCH(CO,~1i-Pr)CO-CAD, ’ BMA-NAPHTHYLALA-NHCH (CO,-i-Pr)CO-CAD, 0
TN i a. ° N-S-TYR (OMe) ~NHCH(CO,~1-Pr) CO=CAD: — _— 0 0
Ion
HN N-S-TYR (OMe) ~NHCH (CO, ~1-Pr) COCR \... 1 0 0 mH
CH3N N-S-TYR (OMe ) -NHCH (CO, -1-Pr)CO-CAD,
A— 1! 0
CH, 0 ~ I : N-S-TYR (OMe) ~NHCH(CO, iPr) COTEADY i
CH, o
BOC~TYR (OMe ) -NHCH (CO, —1-Pr)CO-CAD,
"IVA-TYR (OMe) -NHCH(CO,-i-Pr)CO-CAD,
BMA-TYR (OMe ) -NHCH (CO, ~i-Pr )CO-CAD, 0 7
HN N-S-PHE-NHCH(OEt) CO-CAD, —— 0 0 ~~
CHyN N-S-PHE-NHCH(OEt)CO-CAD,
Nn By
CH, 0 ~N il - N-S-PHE-NHCH (OEt ) CO-CAD, ~~ h
CH, 0
BOC-PHE-NHCH (OEt ) CO-CAD,
EE Bh IVA-PHE-NHCH(OEt )CO-CAD,
BMA-PHE-NHCH (OEt )CO-CAD, 0 an]
O N-S-NAPHTHYLALA-NHCH(OEt)CO-CAD, / a) o i
TN n
HN N-S-NAPHTHYLALA-NHCH (OEt)CO-CAD, : — 1! 0 0
Fama I
CH,4N N-S-NAPHTHYLALA-NHCH(OEt )CO-CAD, \ ; H : : 0
Bh CHg 0 1] _N-S-NAPHTHYLALA-NHCH (OFX) COCAD,
Nn
CH, 0 : Se BOC~-NAPHTHYLALA-NHCH (OEt)CO-CAD,
IVA-NAPHTHYLALA-NHCH (OEt)CO-CAD,
BMA-NAPHTHYLALA-NHCH (OEt)CO-CAD, 0
ITN I o} N-S-TYR(OMe) -NHCH(OEt) CO-CRD. 0 0
Tn
HN N-S-TYR(OMe)-NHCH(OEt)CO-CAD,
Qfeey ' , - 16 - i
PEN
CHN_ N~S-TYR(OMe) ~NHCH(OEE) CO=CADs 0
CHa 9
N-5-TYR (OMe) -NHCH (OEE ) CO-CAD, cu; 0
BOC-TYR (OMe ) ~NHCH (OEt ) CO-CAD,
IVA-TYR (OMe ) -NHCH (OEt ) CO-CAD,
BMA-TYR ( OMe ) -NHCH (OEt ) CO-CAD, 0 o N-S-PHE-NHCH (SCH,)CO-CAD,
SO: 0
AN 'N-5-PHE-NHCH SCHq) CO-CAD/ 70 0
CEN, 'N-S-PHE-NHCH (SCH) CO-CRD > 0 . CH, 0 ™ y- 8 -PHE-NHCH ( SCHy ) CO-CAD, cu,” © oo BOC-PHE-NHCH ( SCH, ) CO~CAD, _ IVA-PHE-NHCH (SCH) CO-CAD, : BMA-PHE-NHCH ( SCH, ) CO-CAD, 9 0 'N-S-NAPHTHYLALA-NHCH(SCHq) CO-CAD: s i
TN ?
EN N-S-NAPHTHYLALA-NHCH (SCH) CO-CRD. 0 — 0
CHgN ‘4-4 -NAPHTHYLALA-NHCH (SCH, ) CO-CAD, \.. / a
EN
> N-S-NAPHTRYLALA-NHCH (SCH) CO-CAD/ cH, O
BOC-NAPHTHYLALA-NHCH ( SCH,) CO-CAD,
v 99°? * . - 17 —-
IVA-NAPHTHYLALA-NHCH({ SCHj,) CO-CAD, .
BMA—-NAPHTHYLALA-NHCH (SCHjy )CO-CAD, 0 [am IW 0 N-S-TYR (OMe) -NHCH (SCH, )CO-CAD, \— i 0 0 .
SN
HN | N-§-TYR (OMe) ~NHCH(SCHa) COZCAD,
Noe 0 0 rN 1
CH,N N-S-TYR (OMe) -NHCH (SCH) CO-CAD, ns I 0
CH, 0 . ~ N-S-TYR(OMe) ~NHCH (SCH,) COTERDY
CH, 0 . 15 BOC-TYR (OMe ) -NHCH(SCH5)CO-CAD, :
IVA-TYR (OMe) -NHCH(SCH3)CO-CAD, i BMA-TYR (OMe ) -NHCH (SCH3)CO-CAD, 0 /\ |! 0 N-S-PHE-NHCH (NMe, ) CO-CAD,
A i 0 0
TN I
HN N-S-PHE-NHCH (NMe, ) CO-CAD, ws . : 0 - 0
Fa i
CH,N N-S-PHE-NHCH { NMe, ) CO-CAD, . ws f 0
CH, 0 ~N 1 _ N-S-PHE-NHCH (NMe,) CO=CRB:
CH, 0
BOC-PHE-NHCH (NMe, )CO-CAD,
I1VA-PHE-NHCH (NMe, )CO-CAD,
BMA-PHE~-NHCH (NMe, ) CO-CAD, 9 0 ‘N-S-NAPHTHYLALA-NHCH (NMe,) CO-CAD,
- 18 ~ 0
TN 1
HN N-S-NAPHTHYLALA-NHCH(NMe, )CO-CAD, ns 0
JR
CH;N N-S-NAPHTHYLALA-NHCH (NMe, ) CO-CAD, \_. J 0
CH, 0 ~~
N-S-NAPHTHYLALA-NHCH (NMe ) CO-CAD, ~~ ) CHa 0
ROC~-NAPHTHYLALA-NHCH (NMe, ) CO-CAD,
IVA-NAPHTHYLALA-NHCH (NMe, )CO-CAD,
RMA-NAPHTHYLALA-NHCH (NMe, )CO-CAD, 0 0, N-S-TYR (OMe) -NHCH (Ne, ) CO-CAD, ~~ 0 0 . TN 1"
HN N-S-TYR(OMe)-NHCH(NMe, )CO-CAD, nr H 0 0 / \ I - 20 CH;N N-S-TYR(OMe )-NHCH(NMe, )CO-CAD, ns 1 0
CH, 0 ~ : _ N-$-TYR(OMe) -NHCH (MMe, ) CO-CAD, : CH, 0
BOC-TYR (OMe ) -NHCH(NMe, ) CO-CAD,
IVA-TYR (OMe ) -NHCH (NMe, ) CO-CAD,
Co BMA-TYR (OMe ) ~-NHCH (NMe, ) CO-CAD, or 0 / \ Hl
HN N~-S-PHE-NHCH[ (CH, ) 4 NHCSNHCH; ]CO-CAD, \ / 1 . . 0 0
TN i
CHsN N-S-PHE-NHCH( (CHp ) 4NHCSNHCH3 ]CO-CAD, \ ; MH 0
CHj a ~ N-§-PHE-NHCH][ (CHz ) 4 NHCSNHCH J CO-CAD, : CHa 0
BOC -PHE-NHCH[ ( CH, ) 4 NHCSNHCH;3 ]CO-CAD,
Co 9430
Lo - 19 -
IVA-PHE-NHCH[ (CH, ) {NHCSNHCH; ]CO-CAD,
BMA-PHE-NHCH( (CH, ) {NHCSNHCH4]CO-CAD, 0 o N-N-NAPHTHYLALA-NHCHI (CH; ) (NHCSNHCH,]CO-CAD, 0 — 1
N_N-S-NAPHTHYLALA-NHCH[ (CHy) NHCSNHCH, }COZCRD, 0
CH,N N-S-NAPHTHYLALA-NHCH( (CH) (NHCSNHCH, }CO-CAD.
Nf 8
CHa 0 > N-§-NAPHTHYLALA-NHCH[ (CHp) qNHCSNICH, | COZCAD:
CH, O oo 15 BOC-NAPHTHYLALA-NHCH( (CH, ) {NHCSNHCH, ]CO-CAD, [VA-NAPHTHYLALA-NHCH( (CHj) JNHCSNHCH; ]CO~CAD,
BMA-NAPHTHYLALA-NHCH({ (CH, ) {NHCSNHCH, ]CO-CAD, : 0 N-S-TYR(OMe)-NHCH( (CH, ) {NHCSNHCH, ]CO-CAD, “0 0
TER OHe) “NHC (Cg) CSIC [CO7CRD: —_ 0
CHgN 'N-8-TYR (OMe) ~NHCH (CH) {NHCSNHCHg | CO=CAD,
So 0 - CHy 0
N-%_TYR (OMe) -NHCH[ (CH, ) {NHCSNHCH; ]CO-CAD, cu” 8
BOC-TYR (OMe ) ~-NHCH( ( CH, ) {NHCSNHCH 1CO-CAD, : IVA-TYR (OMe ) ~NHCH( { CH, ) 4NHCSN:CH,4 ]CO-CAD,
BMA-TYR (OMe ) -NHCH[ ( CH, ) {NHCSNHCH; ] CO-CAD;, a BNMA-NHCH ( CO,CH, ) CO-CAD, 7 | BNMA-NHCH (CO, Et ) CO=CAD,
BNMA-NHCH ( COp—1i-Pr ) CO-CAD,
BNMA-NHCH (OEt ) CO-CAD,
BNMA-NHCH { SCH, ) CO-CAD,
BNMA-NHCH ( NMe, ) CO-CAD,
BNMA-NHCH{ (CH. ) 4NHCSNHCH, ]CO-CAD, lo (CO,CH3) CO—CAD
Va /~\ 0 N /
Ce a (CO,Et) CO= CAD, i c=0 /\ / 0 N _/ x : CH—CO— NHCH (CO,-1-PT) CcO—CAD, / < 0 N—C=0 __/
SS (OEt)CO—CAD, c=0 7 \ / 0 N : _/
i : - 21 - lo /\ < 0 N—C=0 / 0 (NMe,) CO - CAD c=0 / / 0 N _/
CH—CO—NHCH [ (CH,) {JNHCSNHCH3]}CO—CAD , /\ < 0 N—C=0 n__/ . BBSP-TZA-CAD, 0 / \ {i 0 N-S-PHE-NHCH(CO,CH,)CO-CAH, ’ \ 0 n-4 6 N-S-PHE-NHCH(OEt)CO-CAH, 0 0 0 [a Jt lo) N-5-PHE-NHCH( (CH, ) {NHCSNHCH, 1 CO-CAH,
Nand 0 0 ’ / \ H 0 N-S-PHE-LYS(COCHZ)-CAD, ~_/ H
: go?" : ’ - 22 - 0 yam H 0 N-S-PHE-LYS(COH)-CAD, \ / 1 0
BMA-PHE-LYS (COCHj3 )-CAD,
BMA-TYR (OMe ) -LYS (COCHj; ) -CAD, 8 / \ 0 N-S-PHE-LYS (COCH; ) ~CAD,
A y 0 ~~ TN If a 10 CH -N N--PHE-LYS (COCHz ) ~CAD, 7’ \_ J 0 0 —\ ln
CH;-N N-S-PHE-NHCHCO-CAD, }
CH, C=C-CH, NHCOCH, 0 7 tl .
CH3N N-$~PHE-NHCHCO-CAD, oo St : : 0 CH, C=C-CH, NHCOH
BMA-PHE-NHCHCO-CAD,
CH, C=C-CH, NHCOCH;
BBSP-NHCHCO-CAD,
CH, C=C-CH, NHCOCH3
BBSP-LYS (COCH5 )-CAD,
BRSP-NHCH (CO, CHy )CO-CAD, BBSP-NHCH(CO,CpHg )CO=CAD,
BBSP-NHCH ( SCH, CH=CH, ) CO~CAD,
BRSP-NHCH (OCH, CH=CH; )CO-CAD, 0 / \ 1} - CH,N N-S-PHE-NHCH (OCH; CH=CH, )CO-CAD,
Ne H 0 0 ~~
CHaN N-S-PHE-NHCH( SCH, CH=CH ) CO-CAD,
RS
0
BMA-PHE-NHCH ( SCH, CH=CH, )CO-CAD,
BMA-PHE-NHCH ( OCH, CH=CH, )CO-CAD, 0 . anna If
CH3N N-§ - PHE~NHCH (CH, CN) CO-CAD,
SoS ag - 23 -
BMA -PHE-NHCH (CH,CN)CO-CAD,
BBSP-NHCH (CH,CN)CO-CAD, 0 fan . °_ N~-§-PHE-NHCH ( SCH, C=CH) CO=CAD,
C0 0 ran
O_ N-§-PHE-NHCH(OCH,C=CH)COTCAD, 0
BMA-PHE-NHCH ( SCH,C=CH) CO-CAD,
BMA -PHE-NHCH (OCH,C=CH)CO-CAD,
BBSP-NHCH ( SCH,C=CH)CO-CAD, and
BBSP-NHCH (OCH,C=CH)CO-CAD.
Most preferred compounds are: . 0 .
Lo / o N-§-PHE-NHCH CO, CHg) CO-CAD, } _! 0
CH oO
IN dl _ N-S-PHE-NHCH ( CO,CHy) CO-CAD, 1
CH, 0 0
Nl °L N-S-PHE-NHCH (OEE) CO-CAD (fast isomer), : 1 . ' 0 0
NN . °_ N-S-PHE-NHCH(OEt)CO-CAD (slow isomer), 1 \_ 25 0 oO .
Nl 0 N-S-NAPHTHYLALA-NHCH (CO,CH;)CO-CAD,
Nt ll 0
BBSP-HIS-CAD (slow isomer),
BBSP-HIS-CAD (fast isomer), 0 .
STN i 0 N-§-PHE-NHCH (CO, ~i-Pr)CO=CAD, eS . 0 - 1VA-PHE-NHCH (CO,CH3) CO-CAD,
’ CH, 0 ~ MH __NS-TYR(OMe) ~NHCH(CO;CHy) COCA: : CH, 0 0 . fame I} oO N-S-TYR(OMe) ~NHCH (CO, CHg) COCAD
Nt \ 3
Oo 0)
A 1 0 N-S-PHE-NHCHCO-CAD, nr 0 CH,C=C-CH,NHCOCH; 0 —/ : 0 N-S-PHE-NHCHCO-CAD, w/ \ 0 CH,C=C-CH,NHCOH 0 s/n . 0 N-S-PHE-NHCHCO-CAD, ll i 0 CH,C=C~-CH,NHCSNHCH4 1 . °L N-§-PHE-NHCH(SEt)CO-CAD (fast isomer), od 1 : 0 0
Sy } 0 N-S-PHE-NHCH(SEt)CO-CAD (slow isomer), —/ h 0 on Jes : : 0, N-S-PHE-NHCH(S g” )CO-CAD, : - 70 0
VE i ] 0 N- -PHE-NHCH (OCH,CH=CH, ) CO-CAD (fast isomer), . i rs 1 oe 0 0
Nt . 0 N-§-PHE-NHCH (OCH, CH=CH) CO=CAD (slow isomer), nS 0
BMA-PHE-NHCH (OEt )CO-CAD, 0
NN n 0 N-§-PHE-NHCH(SCH,CH=CH,)CO~CAD (fast isomer), / i . 0 . 0
Sy . 0, N- $-PHE-NHCH (SCH, CH=CH, ) CO=CAD (slow isomer), ot 1 0
TTS
2Je3% . . ' - 25 - ’ BOC-PHE-NHCH(SEt )CO-CAD (fast isomer),
BOC-PHE-NHCH(SEt )CO-CAD (slow isomer), 0
IN oO N-S-PHE-NHCH (CH,CN)CO-CAD,
NE
0 — 2 oO N-S-PHE-NHCH(OEt )CO-CAH,
NLS oO 0
STN
HN NS -PHE-NHCH (CO,CH, yCO-CAD, —
Oo 0
SN
CHsN N-S-PHE-NHCH(CO,CH4)CO-CAD, ns H oO 0
Hl e. ° _N-S-PHE-NHCH(CO,H)CO-CAD, —_ 1 oO oO
Nn o N-S-PHE-GLY-CAD, and
AA
0 : 0
Oo N-S-PHE-LYS(CSNHCH,)-CAD.
Nn i 0
The compounds of the present invention have the advantage of increased hydrophilicity. This property makes a the compounds more readily absorbed. Compounds of the invention have demonstrated in vivo activity.
The compounds include solvates and hydrates and pharmaceutically acceptable acid addition salts of the basic compounds of formula I above.
The term pharmaceutically acceptable acid addition salt is intended to mean a relatively nontoxic acid addition salt either from inorganic or organic acids such as, for example, hydrochloric, hydrobromic, hydroiodic, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylie, malic, benzoic, gluconic, fumaric, succinic, ascorbic, maleic, tartaric,
fod i . - 26 - . methanesulfonic, and the like. The salts are prepared by contacting the free base form with a sufficient amount of the : desired acid to produce a salt in the conventional manner.
The free base forms may be regenerated by treating the salt form with a base.
The modified peptides of the present invention possess one or more chiral centers and each center may exist in the
R{D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms as well as the appropriate mixtures thereof. Additionally, the preferred stereochemistry for W is as depicted below. ® OH OH ~NH-CH--CH-CH-CH,CH(CH,) oo Rio ® © wherein R,;, is as defined above.
Some of the above novel peptides may be prepared in accordance with well-known procedures for preparing peptides from their constituent amino acids. Other of the novel peptides of the present invention are prepared by a step-wise procedure or by a fragment coupling procedure depending upon the particular final product desired. - The following scheme illustrates novel methods of preparing certain peptides of the present invention.
LL
Ion te - 27 -
Scheme I — 0
O N-S-PHE + H,NCHCO,CH,Ph il ! ’ 0 CO,CH, (1) (2)
Faun ©
O _ N-§-PHE-NHCHCO,CH;Ph — 3 0 CO,CHgq (3) — 9 HoNCH (CH, ))CH(OH) CH (OH) CH, CH (CH, ), oO N-S-PHE-NHCHCO,H EE —. = C0,CH, (5) (4)
ST 0 0 N-S-PHE-naCHCO-NHCH (CH, < JCH(OH)CH(OH)CH,CH(CHy) o) CO,CH, (6)
According to Scheme I above, morpholinosulfamylphenyl - alanine (1) is reacted with amino malonate methyl benzyl ester (2) to form the diester (3). The reaction takes place in an inert solvent such as methylene chloride or DMF with hydroxybenzotriazole and dicyclohexylcarbodiimide at
A temperatures from 0°C to 25°C.
The benzyl ester (3) is reacted with hydrogen gas in the presence of a catalyst such as 10% on palladium on charcoal : to afford the carboxylic acid (4). The reaction takes place in a solvent such as methanol.
The carboxylic acid (4) is then reacted with amine (5) in an inert solvent such as methylene chloride or DMF with
HOBT and DCC at temperatures from 0°C to 25°C to form (6), a compound of the present invention.
2Jezte } . - 28 -
Scheme 11
BOC NHCHCO,H + H,NCHCH=CH-CH,CH(CH,), ——
CO,CHj, (1) (2)
BOC NHCHCO — NHCHCH=CH~ CHzCH (CH3) 2 mem. : . CO,CH, (3) ou ou
BOC NHGHCO™— NHCHCH - CH-CH,CH (CH) 5 —— : CO,CH; (4) . or OH OH O N-SO,-PHE
I /
HEL * HZNEHCO—NHCHCH- CH -CH,CH (CH) 5 —_—
CO,CH, (6) (5)
OH OH
7 \ I 0 N—S0, = PHE — NHCHCO —— NHCHCH - CH~- CH,CH (CH;) , \__/
L.. CO,CH; (Nn
According to Scheme II above, methyl BOC-amino-malonate (1) is reacted with the unsaturated amine (2) to form (3). : The reaction takes place in an inert solvert such as DMF,
CHpCl,, or THF with HOBT and DCC at temperatures from 0°C to 25°C.
Compound (3) is hydroxylated to compound (4) in THF using N-methyl-morpholine-N-oxide and catalytic amounts of
] osmium tetroxide. The reaction is run at room temperature for one to three days.
Removal of the BOC-group to give (5) can be accomplished with HCl gas in CH,Cl, or CHCl, at room temperature for one to four hours.
Pan
Coupling with 0 N-50,-PHE (6) to give (7) is pa accomplished in an inert solvent such as DMF, CH,Cl,, or THF using an organic base such as Et3N to neutralize the HCl salt present. The coupling is accomplished with DCC and HOBT at temperatures from 0°C to 25°C.
Scheme ITT /\ 0 N— 50, = PHE — NHCHCO,H + H;NCHCH=CH-CH,CH (CH,) \ ; | 2 2 2 3/2
CO,CH;4 (1) (2) : /N\ —= 0 N= 50; — PHE — NHCHCO — NHCHCH = CH- CH,CH (CH) \ , | 2 3/2 \
CO,CH, (3) a OH OH /\ I = 0 1 8027 PRET NHCHCO — NHCHCH~ CH~ CH, CH (CH3) 5
CO,CH,4 (4)
According to Scheme III above, reaction of (1) with (2) in an inert solvent such as DMF, CH,Cl,, or THF with DCC and
HOBT at temperatures from 0°C to 25°C gives (3).
Compound (3) is hydroxylated to (4) in THF using
N-methylmorpholine-N-oxide and a catalytic amount of osmium
9Fo2Y - 30 - tetroxide. The reaction is run at room temperature for one to three days.
The strategy of peptides chain assembly and selection and removal of protecting groups is discussed in Chapter 1, "The Peptide Bond," in "The Peptides. Analysis, Synthesis,
Biology," E. Gross and J. Meienhofer, Eds., Academic Press, —- New York, NY, 1979, Vol. 1, pp. 42-44. pa The DCC/HOBT method of coupling is well-known to those skilled in the art and is discussed in Chapter 5, "The
Carbodiimide Method" by D.H. Rich and J. Singh in "The
Peptides. Analysis, Synthesis, Biology," E. Gross and J.
Meienhofer, Eds., Academic Press, New York, NY, 1979, Vol. 1, pp. 241-261.
Peptide coupling depends on activating the carboxy terminus of the amino protected amino acid and condensing it - with another peptide containing a free amino terminus. In addition to the DCC coupling method described above, other methods of activating the carboxyl group of a protected amino acid include: 1) The azide method - described in Chapter 4 of the above reference. 2) The mixed anhydride method - described in Chapter 6 of the above reference. ° 3) The active ester method - described in Chapter 3 of the above reference.
The term lower alkyl refers to straight or branched rt chain alkyl radicals containing from 1 to 6 carbon atoms including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, 2-methylhexyl, n~-pentyl, l-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl, and the like.
Aryl means phenyl, naphthyl or other aromatic groups, including mono- or bicyclic, which may be substituted, especially monosubstituted, by F, C1, Br, I, CF,, OH, OR, or
R, wherein R is lower alkyl.
Heteroaryl means aromatic heterocyclic rings containing at least one heteroatom selected from O, S, and N and from
203 b
A - 31 - 3 to 5 carbon atoms including but not limited to thiazoles and imidazoles.
Aralkyl is as described above for alkyl and aryl, including but not limited to benzyl.
The compounds of the present invention are useful for treating renin-associated hypertension, congestive heart failure, and hyperaldosteronism. They are also useful as diagnostic tools for determining the presence of renin- associated hypertension or hyperaldosteronism.
Pharmaceutical compositions which comprise an effective amount of the compound in combination with a pharmaceutically acceptable carrier are part of the present invention. An important aspect of the present invention is a method of treating renin-associated hypertension in a mammal which . 15 comprises administering a pharmaceutical composition ee containing an effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrrier to the mammal. :
Another equally important aspect of the present invention is a method of treating hyperaldosteronism in a : mammal which comprises administering a pharmaceutical composition containing an effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier to the mammal.
An additional aspect of the present invention is a method for treating congestive heart failure in a mammal which comprises administering a pharmaceutical composition containing an effective amount of a compound in combination with a pharmaceutically acceptable carrier to the mammal.
Yet another aspect of the present invention is a process for preparing a compound of formula I wherein Y is ~NH-CH-CO-
COzRy, wherein R;, is hydrogen lower alkyl, alkenyl, alkynyl or aralkyl which comprises: . a) reacting an N-sulfamyl amino acid with a primary amine to : form the corresponding N-sulfamyl benzyl methyl ester;
2FoB¥ : - 32 - ; b) reacting the N-sulfamyl benzyl methyl ester with hydrogen gas in the presence of a catalyst to form the corresponding
N-sulfamyl methyl ester acid; and
Cc) reacting the N-sulfamyl methyl ester acid with the 5 appropropriate free amine to form a desired compound of !
Claim 1, formula I; d) optionally hydrolyzing the methyl ester to the free acid to form a desired compound of Claim 1, formula I.
Yet another aspect of the instant invention is a process for preparing a compound of formula I wherein Y is -NH-CH-CO-, -NH-CH-CO-, -NHCH-CO-, -NH~CH-CO- or -NH-CHCO-
SR, SO-R, OR, NHR, NN
R; Rg wherein R; is lower alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, (CHp ) -NHR,, wherein n is an integer of from 2 to 4,
R, is C-NHCH , C-NHCH3, C-NHNO,, C-SCHj, C-NHCH3, C-Rj, oT 0 S NH NCN NCN 0
C-CHNHRs , (-CH, CH, NHC-Rs, R; is hydrogen, lower alkyl, or aryl, 0 Ry 0 0
Ry is H, lower alkyl or aralkyl, Rs is C-NHCHj , C-NHCHg , C-NHNO, , 0 S NH
C-5CH,, G~NHCH3, C-Rg, Rg 1s hydrogen, lower alkyl or aryl,
NCN NCN 0 . R, is Ry, C-NHCHs, C-NHCH3, G-NHNO,, C-SCHj, C-NHCHy, 0 S NH NCN NCN
C-Rs, C-ORy, C~CH-NHR , G~CHa CH, NER; , H, Rg is lower
Co 0 0 0 Ry 0 hat alkyl or together with R;, when R; is lower alkyl, forms a heterocyclic ring containing from 4 to 6 carbon atoms optionally containing one or more S, O, or NR; Rg is alkyl or aralkyl; R,, is lower alkyl or aralkyl, which comprises: (a) reacting morpholinosul famyl-PHE-NH, with glycxylic acid in acetone to produce morpholinosulfamyl-PHE-o-hydroxy glycine; (b) reacting the morpholinosul famyl-PHE-a~hydroxy~-glycine in ethanol-sulfuric acid to produce morpholinosulfamyl-PHE-a- ethoxyglycine, ethyl ester; rd
; oo - 33 - (c) or optionally reacting the glycine of a) above with ethanethiol in the presence of HOAc-H,SO, to produce
Q_ N-SO, ~PHE-NHCH(SEt ) CO, H; (d) hydrolyzing the ethyl ester of b) above in the presence of base to produce morpholinosulfamoyl-PHE-o-ethoxyglycine; and (e) reacting the products of (c) or (d) above with the appropriate free amine to produce the desired compound of
Claim 1, formula I.
Yet another aspect of the instant invention is a process for preparing a compound of formula I wherein Y is -NH-CH-CO wherein n is an integer of from 2 to 4 and R, is (CHz) py . NHR, -NHCH, , §~NHCH, , G~NHNO. , C=SCHs, C-NHCH;, C-Ra. -G-CHNHRs ,
Oo Ss NH NCN NCN 0 0 Ry (~CH2 CH, NHC-Rs , R; is hydrogen, lower alkyl, or aryl, Ry 0 0 is H, lower alkyl or aralkyl, Rg is C-NHCH; , C-NHCH, , 0 S
C-NHNO, , C-SCH,, C-NHCH3, C-Re Re¢ 1s hydrogen, lower alkyl
NH NCN NCN 0 or aryl, R; is Ry, C-NHCH;, C-NHCH,, C-NHNO,, C-SCHy , 0 S NH NCN 3 C-NHCH3, C-Ry, C-ORy, C-CH-NHRs, C-CH,CH,NHRs, H, Rg is
NCN 0 0 0 Ry 0 lower alkyl, forms a heterocyclic ring containing from 4 to 6 carbon atoms optionally containing one or more S, O, or NR; ce Rg is alkyl or aralkyl; Ry, is lower alkyl or aralkyl, which comprises: (a) reacting BOC-LYS(Z) with l-cyclohexyl-2-amino-3,4- dihydroxy-6-methylheptane to produce BOC-LYS(Z)-CAD, (b) reacting BOC-LYS{Z)-CAD with a strong acid to produce
LYS(2)-CAD, (c) coupling LYS(Z)-CAD with morpholinosul famyl-PHE to produce morpholinosulfamyl-PHE-LYS(Z)-CAD, (d) removing the Z from the product of step (c) above to i» produce morpholinosulfamyl-PHE-LYS-CAD, and
JUL
I - 34 - (e) reacting the product of step (d) above with the desired acylating agent to produce a desired compound of Claim 1, formula I.
Yet another aspect of the instant invention is a process for preparing a compound of formula I wherein Y is -NHCHCO-
CH, CN which comprises: (a) treating Z-ASN in pyridine with DCC to give Z-NHCHCO, H,
CH, CN (b) reacting Z-NHCHCO, H with l-cyclohexyl-2-amino-
CH, CN 3,4-dihydroxy-6-methylheptane to produce 2-NHCHCO-CAD, ~ CH, CN (c) removing the Z-group with hydrogen in the presence of palladium on carbon to give Hz NCHCO-CAD,
CH, CN (d) coupling the product of c) above with morpholinosul famyl-
PHE using DCC to give a desired compound of formula I.
Yet another aspect of the instant invention is a process for preparing a compound of formula I wherein Y is ~NHCHCO- wherein R, is C-NHCy , C-NHCH3 , C-NHNO ,
CH, C=C~CH, NHR, 0 S NH (-SCHs, C-NHCH;, C-Rs, C-CHNHRs, CCHpCH,NHC-Rs, Rg is i. NCN NCN O O Ry 0 oO hydrogen, lower alkyl, or aryl, Rs is H, lower alkyl, or aralkyl, Rg is C-NHCH3, C-NHCHj, C-NHNO, , C-SCHj, C-NHCH; , 0 S NH NCN NCN - C-Re , Re¢ is hydrogen, lower alkyl, or aryl, which comprises: 0 (a) reacting morpholinosulfamyl-PHE with diethyl amino- malonate-HCl in the presence of a coupling agent to give
O__N-SO, -PHE-NHCH(CO, Et), (b) alkylating the malonic ester with Cl1CH,C=C-CH,NHBOC in the presence of NaH to give Q_ N50, ~PHE-NHC (CO, Et) 35 . CH, C=C~CH, -NHBOC
Jed . Cas (c) hydrolyzing the ester with NaOH and decarboxylating the malonic acid by heating in dioxane/toluene to give
Q_N-S0; ~PHE-NHCHCO, H,
CH, C=C-CH, NHBOC (d) coupling the product of (c) above with l-cyclohexyl-2- amino-3, 4-dihydroxy-6-methylheptane with DCC to give o_N-50; ~PHE-NHCHCO-CAD,
CH, C=C-CH, NHBOC (e) removing the BOC-group with HCl gas in dichloromethane to give O__N-50; -PHE-NHCHCO=CAD,
CH, C=C-CH, NH, (f) reacting the product of (e) above with an appropriate
Co acylating agent to give a desired compound of formula I.
Preferably in step (a) above the coupling agent is DCC.
The effectiveness of the aforementioned compounds is : determined by a test for in vitro renin inhibitory activity. oC This activity is determined by a standard radioimmunoassay for angiotensin I. In this assay the enzyme, renin, incubated for two hours at 37° in the presence of a substrate, angiotensinogen, generates the product, angiotensin I. Test compounds are added to the incubation mixture. Relative activity is reported as the ICsq., which is the molar concentration of test compound causing a 50% - inhibition of the renin activity. ~ {
Compound ICq0 (nM) . 203 } ° . Hl : 0 NS-PHE-NHCH (CO,CH, } CO-CAD 0.14 ; — : 0 0
ML ] 0 NS-PHE-NHCH(CO,-1-Pr )CO-CAD 0.68
Nes I 0 °
Nh . 0 NS -PHE-NHCH (OEE) CO-CAD (fast isomer) 0.25 “. 0 i 0
Nl 0 Ni -PHE-NHCH (OEE) CO-CAD (slow isomer) 1.4 0
CH, 0
NO
. _ NS-TYR(OMe)-NHCH(CO,CHy)CO-CAD 0.68 i
CH; O i rh 0 NS -NAPHTHYLALA-NHCH(CO,CH,) CO-CAD 0.6 eo 0
CH, 0 - ONL , . _ NS-PHE-NHCH(CO,CH3) CO-CAD 0.66
SL.
CH, J
IVA-PHE~NHCH(CO,CH,4)CO-CAD 1.4 0 mT n 0 N-S-TYR (OMe ) -NHCH (CO, CH4 ) CO-CAD 0.45
No } 0
BBSP-HIS~-CAD (slow isomer) 0.8
BBSP-HIS-CAD (fast isomer) 160 gfo2 : . - 37 -
TABLE II (Continued)
Compound ’ ICq (nM) 0
Nl 0 N-S-PHE-NHCHCO-CAD 7.6 ns b CH,C=C-CH,NHCOCH, 0
A i 0 N= PHE-NHCHCO-CAD 6.0
No 0 CH,C=C-CH,NHCOH 0
TN I
0 Nj ~PHE-NHCHCO-CAD 24.0 \ 1 - 0 CH,C=C-CH,NHCSNHCH, 0 .
Nd . 0 N-S-PHE-NHCH(SEt)CO-CAD (fast isomer) 0.13
Noo “ 0 0 i i 0 N= PHE-NHCH( SEt)CO-CAD (slow isomer) 18.0
A
0 0 . TN 4 : ° N-5-PHE-NHCHCO-CAD 13.0
C0 | 3 s—L J - 0
Nl . 0 N-5-PHE-NHCH (OCH,CH=CH, )CO-CAD (fast isomer) 0.045 ns 4 0
SRE } 0 N-5-PHE-NHCH ( OCH, CH=CH, )CO-CAD (slow isomer) 1.1 -— 0 .
BMA-PHE-NHCH (OEt ) CO~-CAD 1.4
9 1 03% - 38 =-
TABLE II (Continued)
Compound ICsq (nM) 0
SN | i 0 N-5-PHE-NHCH (SCH, CH=CH, ) CO-CAD (fast isomer) 0.17
A 5 0 0
Vana . 0 N-§-PHE-NHCH (SCH, CH=CH; ) CO-CAD (slow isomer) 38.0 . 0
BOC-PHE-NHCH(SEt)CO-CAD (fast isomer) ’ 1.4
BOC-PHE-NHCH(SEt)CO~CAD (slow isomer) >10.0 0 - NO o N-S~-PHE-NHCH( CH, CN)CO-CAD 0.4 \__ 7 1 : 0 0
Nl 0 N-5-PHE-NHCH(OEL)CO-CAH 25.0 7 0 0
TN
HN' N-S-PHE-NHCH(CO, CH; )CO-CAD 0.6 ws oO 0
TN
CH3N N-S~-PHE-NHCH (CO, CH, )CO-CAD 0.3 _/ - 0 0
TN
° N-5&-PHE-NHCH(CO,H)CO-CAD 12.0
Ss 0 .“. o
TN
: 0 N-S-PHE-GLY-CAD 5.0
Nn I . 0 0 /™ " 0 N-S-PHE-LYS (CSNHCH,4 )~CAD 0.19 / H vals i . “1 : - 39 - . A
When O__/N-S02-PHE-NHCH(CO, CH; )CO-CAD was administered orally at 10 or 30 mg/kg to high renin hypertensive Cynomolgus monkeys, it showed a dose dependent reduction in blood pressure. At 30 mg/kg PO it showed a 24 mm Hg reduction in blood pressure two hours post dose. The plasma renin activity at this time was inhibited by >98%.
As can be seen from the above results, the compounds of the present invention have a significant effect on the activity of renin and thus are useful for the treatment of hypertension, hyperaldosteronism, and congestive heart failure.
For preparing pharmaceutical compositions from the : compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories. te A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; co it can also be encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active compound. In the tablet the active compound is mixed with carrier having the necessary binding properties in suitable proportions and compacted in the shape - 25 and size desired. The powder and tablets preferably contain from 5 to 10 to about 70 percent of the active ingredient.
Suitable solid carriers are magnesium carbonate, magnesium
LL stearate, talc, sugar, tragacanth, methylcellulose, a low melting wax, cocoa butter, and the like. The term "preparation" is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component (with or without other carriers) is surrounded by carrier, which is thus in association with it. Similarly, cachets are included. Tablets, powders, cachets, and capsules can be : used as solid dosage forms suitable for oral administration.
The compound of the present invention may be administered orally, buccally, parenterally, by inhalation A spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants and vehicles as desired. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.
For preparing suppositories, a low melting wax such as a mixture of fatty acid glycerides or cocoa butter is first melted, and the active ingredient is dispersed homogeneously therein by stirring. The molten homogeneous mixture is then
To poured into convenient sized molds, allowed to cool, and thereby solidify
Liquid form preparations include solutions, suspensions, and emulsions. As an example may be mentioned water or water/propylene glycol solutions for parenteral injection.
Liquid preparations can also be formulated in solution in aqueous polyethyleneglycol solution. Aqueous suspensions suitable for oral use can be made by dispersing the finely oo divided active component in water with viscous material, i.e., natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known : N suspending agents.
Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form
Lo preparations for either oral or parenteral administration.
Such liquid forms include solutions, suspensions, and emulsions. These particular solid form preparations are most conveniently provided in unit dosage form and as such are used to provide a single liquid dosage unit. Alternately, sufficient solid may be provided so that after conversion to : liquid form, multiple individual liquid doses may be obtained by measuring predetermined volumes of the liquid form preparation as with a syringe, teaspoon, or other volumetric container. When multiple liquid doses are so prepared, it is preferred to maintain the unused portion of said liquid doses
: [03 ; % - 41 - - ‘at low temperature (i.e., under refrigeration) in order to retard possible decomposition. The solid form preparations intended to be converted to liquid form may contain, in addition to the active material, flavorants, colorants, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
The liquid utilized for preparing the liquid form preparation may be water, isotonic water, ethanol, glycerine, propylene glycol, and the like, as well as mixtures thereof.
Naturally, the liquid utilized will be chosen with regard to the route of administration, for example, liquid preparations containing large amounts of ethanol are not suitable for parenteral use.
Preferably, the pharmaceutical preparation is in unit dosage form. In such form, the preparation is subdivided
Cy into unit doses containing appropriate quantities of the - active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, for example, packeted tablets, capsules, and powders in vials or ampules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these in packaged form.
The quantity of active compound in a unit dose of preparation may be varied or adjusted from 1 mg to 500 mg, preferably 5 to 100 mg according to the particular application and the potency of the active ingredient. The compositions can, if desired, also contain other compatible ; therapeutic agents.
In therapeutic use as renin inhibitors, the mammalian dosage range for a 70 kg subject is from 1 to 1500 mg/kg of body weight per day or preferably 25 to 750 mg/kg of body weight per day optionally in divided portions. The dosages, however, per day may be varied depending upon the : requirements of the patient, the severity of the condition
Vo 35 being treated and the compound being employed. Determination of the proper dosage for a particular situation is within the skill of the art. Generally, treatment is initiated with
: He3¥ - 42 - small dosages which are less than the optimum dose of the compound. Thereafter the dosage is increased by small : increments until the optimum effect under the circumstances is reached. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.
The following examples are provided to enable one skilled in the art to practice the present invention. These examples are not intended in any way to limit the scope of the invention but are illustrative thereof.
I EXAMPLE 1 o } 0 N-8-PHE-NHCH (CO,CH,;)CO-CAD i
Ln 15 A mixture of morpholinosulfamyl-PHE-NHCH(CO,CH,)CO,H (0.5 g), DCC (0.25 g), HOBT:-H,0 (0.16 g) and 10 ml DMF is stirred at 25° for ten minutes. The resulting slurry is treated with a solution of HCH (cH { )CH=CHCH,CH(CHg) , (0.30 g) in 5 ml DMF. After stirring at 25° for 24 hours the reaction is filtered and concentrated under vacuum. The ~ residue is dissolved in CH,Cl, (75 ml) and this solution is washed with 5% aqueous Na,CO; (25 ml), dried over MgSO,, and evaporated. The major product is isolated by flash
Lo chromatography on silica gel.
This product (0.4 g) is dissolved in THF (10 ml) and
N-methylmorpholine-N-oxide (0.22 g) and osmium tetroxide (0.01 g) is added. The reaction mixture is stirred for 72 hours and is filtered and concentrated under vacuum. The residue is dissolved in ethyl acetate (75 ml) and washed with 10% Na,SO5 (25 ml), 10% citric acid (25 ml), saturated aqueous
NaHCO; (25 ml) and saturated aqueous NaCl (25 ml). The major product is isolated by flash chromatography on silica gel, eluting with CHCl,-MeOH (99:1) to afford a crisp foam upon )
29o3t . - 43 - evaporation of solvents. MS (FAB) 655 (m+l). (FAB is fast atom bombardment).
EXAMPLE 2 oO 0 N-S-PHE-NHCH(CO,CH, ) CO~CAD ~~ 8
A mixture of morpholinosulfamyl-PHE-NHCH(CO,CH;)CO,H (0.5 g), DCC (0.25 gq), HOBT-H,0 (0.16 g) and 10 ml DMF was stirred at 25° for ten minutes. A solution of ancH (cH, < ) )CH(OH)CH(OH)CH,CH(CHg),-HCl and
N-methylmorpholine (0.15 ml) in 10 ml DMF was added to the slurry and stirred for 48 hours. The reaction was filtered
Lo and concentrated under vacuum. The residue was dissolved in
EtOAc (200 ml) and this solution was washed with water (100 ml), saturated aqueous NaHCO; (100 ml), water (100 ml) and saturated sodium chloride (50 ml), dried over MgSO,, and evaporated. The product was isolated by flash chromatography on silica gel. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for C3 HggN409S (MW 654.74): re = C, 56.86; H, 7.70; N, 8.56
Found: C, 56.44; H, 7.61; N, 8.86
EXAMPLE 3 o (CH ) ;N-$-PHE-NHCH (CO,CHy ) CO-CAD 0 .
Substitution of dimethylsulfamyl-PHE-NHCH(CO,CH,)CO,H for morpholinosulfamyl-PHE-NHCH(CO,CH;)CO,H in Example 2 afforded the desired product whose structure was confirmed by
NMR and mass spectroscopy.
Calcd. for CygH,sN,05S (MW 612.71):
C, 56.84; H, 7.90; N, 9.15
Found: C, 57.19; H, 8.20; N, 9.29
- a4 -
EXAMPLE 4 0 0 N-5-PHE-NHCH(OEt ) CO-CAD
Ns
Substitution of morpholinosulfamyl-PHE-NHCH(OEt)CO,H for morpholinosul famyl-PHE-NHCH(CO,CH;)CO,H in Example 2 afforded the desired product. Chromatography on silica gel, eluting with a gradient of 0-2% MeOH in CHCl,;, gave the fast moving diastereomer. The structure was confirmed by NMR and mass spectroscopy.
Caled. for C,,Hg,N 03S (MW 640.76):
C, 58.10; H, 8.18; N, 8.74 - Found: C, 58.12; H, 8.33; N, B.43 : Continued elution from the column gave the slow moving - 15 diasteromer. The structure was confirmed by NMR and mass
Po spectroscopy. = Caled. for Cg HgyN4OgS (MW 640.76): i ’ Cc, 58.10; H, 8.18; N, 8.74
Found: C, 58.60; H, 8.41; N, 8.56
EXAMPLE 5 8 0 N-S-NAPHTHYLALA-NHCH (CO,CH,4 ) CO-CAD
CL — I ’
A mixture of morpholinosulfamyl-NAPHTHYLALA-
NHCH(CO,CH4)CO,H (0.5 g), DCC (0.25 g), HOBT-H,0 (0.16 g) and 10 ml DMF is stirred at 25° for 10 minutes. The resulting ~ slurry is treated with a solution of
NH CH (CH) )JCH=CHCH,CH(CH,), HCl and N-methylmorpholine (0.15 ml) in 10 ml DMF. After stirring at 25° for twenty-four hours the reaction is filtered and concentrated.
The residue is dissolved in EtOAc (75 ml) and this solution is washed with 5% aqueous Na,CO; (25 ml), dried over MgSO, and evaporated. The major product is isolated by flash chromatography on silica gel.
9703¢ : - 45 -
This product (0.4 g) is dissolved in THF (10 ml) and
N-methylmorpholine-N-oxide (0.22 g) and osmium tetroxide (0.01 g) is added. The reaction mixture is stirred for seventy-two hours and is filtered and concentrated. The residue is dissolved in EtOAc (75 ml) and washed with 10%
Na,S0O,; (25 ml), 10% citric acid (25 ml), saturated aqueous
NaHCO; and saturated aqueous sodium chloride (25 ml). The major product is isolated by flash chromotography on silica gel.
EXAMPLE 6 ~~ oO N-S-NAPHTHYLALA-NHCH(CO,CH4)CO-CAD — 8
A solution of 560 mg (1.17 mmole) of morpholino- ‘_.. 15 sulfamyl-NAPHTHYLALA-NHCH(CO,CHz)CO,H, 360 mg (1.29 mmole) of nner (cH, <) )CH(OH)CH(OH)CH,CH(CH,y),-HC1l, and 174 mg } (1.29 mmole) of HOBT in 25 ml CH,Cl, was treated with 0.24 ml 4 (1.75 mmole) of Et4N followed by 266 mg (1.29 mmole) of DCC and the mixture allowed to stir at room temperature overnight. The solvent was removed under reduced pressure - : and the residue taken up in EtOAc. After filtering, the
EtOAc was washed with H,0, saturated NaHCO,, and saturated
NaCl. Drying over MgSO, and removal of the solvent under _ reduced pressure gave the crude product which was purified by chromatography on silica gel, eluting with a gradient of 0-2%
MeOH in CHCl. The structure of the product was confirmed by
NMR and mass spectroscopy.
Calcd. for CggHg,N40oS-0.1CHCl, (MW 716.74):
Cc, 58.82; H, 7.33; N, 7.82
Found: C, 58.75; H, 7.44; N, 7.57
EXAMPLE 7 0 ‘anY 0 N-S-PHE-NHCH(CO,-i-Pr )CO-CAD — 8 d 5 Substitution of morpholinosulfamyl-PHE-NHCH(CO,-i
Pr)CO,H for morpholinosulfamyl-PHE-NHCH{CO,CH;)CO,H in
Example 2 afforded the desired product whose structure was confirmed by NMR and mass spectroscopy.
Calcd. for C,3Hg N,04S (MW 682.79): c, 58.05; H, 7.97; N, 8.21
Found: CC, 58.04; H, 7.92; N, 7.99 - EXAMPLE 8
CH, 0 ~~.
N-S-TYR (OMe) -NHCH(CO,CH43) CO-CAD \ 15 cu,” 4 :
Substitution of dimethylsulfamyl-TYR (OMe)
NHCH(CO,CH4)CO,H for morpholinosulfamyl-NAPHTHYLALA
NHCH(CO,CH,4)CO,H in Example 6 afforded the desired product whose structure was confirmed by NMR and mass spectroscopy.
Calcd. for CyoHgoN404S (MW 642.73):
C, 56.06; H, 7.84; N, 8.72
Found: C, 56.12; H, 7.81; N, 8.90
EXAMPLE 9 oO _ 25 0” N-§-TYR (OMe) -NHCH(CO,CH, ) CO-CAD w/o
Oo
Substituting morpholinosulfamyl-TYR(OMe)-
NHCH(CO,CH4)CO,H for morpholinosulfamyl-PHE-
NHCH(CO,CH5)CO,H in Example 2 afforded the desired product which was purified by chromatography on silica gel, eluting with a gradient of 0-4% MeOH in CHCl,. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for Cj,H5,N40,4S (MW 684.77):
C, 56.12; H, 7.65; N, 8.18
Found: CC, 55.82; H, 7.78; N, 8.24
Ged . - 47 - Co
EXAMPLE 10
IVA-PHE-NHCH(CO,CH4)CO-CAD
Substituting IVA~PHE-NHCH(CO,CH4)CO,H for morpholinosulfamyl~PHE~NHCH(CO,CH,;)CO,H in Example 2 afforded the desired product whose structure was confirmed by NMR and mass spectroscopy.
Calcd. for Cg,Hg;NgO, (MW 589.75):
C, 65.17; H, 8.72; N, 7.13
Found: C, 65.03; H, 8.68; N, 7.39 i . _—
EXAMPLE 11
Co
Co BBSP-HIS-CAD (Isomer A) \ :
A solution of 1.6 g (1.8 mmole) of BBSP-HIS(TRT)-CAD (fast moving isomer) in 100 ml of 80% HOAc was warmed on a steam bath for five minutes, then diluted with 200 ml of H,0.
After extracting with Et,0, the aqueous solution was concentrated. The suspension obtained on diluting with H,0 was made basic with NaHCO;, and extracted with CHClg. The
CHCl; was washed with saturated NaCl and dried over Na,SO4. - After removal of the solvent under reduced pressure, the residue was chromatographed on silica gel, eluting with a oo gradient of 0-4% MeOH in CHCl,. There was obtained 0.53 g of or pure product. This was converted to the methanesulfonic acid salt, dissolved in H,0, and freeze-dried. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for Cy4Hg4N40gS-CH3S03H-2.3 H,0 (MW 784.28):
C, 53.60; H, 8.05; N, 7.14
Found: CC, 53.57; H, 7.83; N, 7.00
EXAMPLE 12 :
BBSP-HIS~-CAD (Isomer B)
Using 2.2 g (2.48 mmole) of BBSP~-HIS(TRT)-CAD (slow moving isomer) and proceeding as in Example 11, there was obtained 0.93 g of product. This was converted to the methanesulfonic acid salt, dissolved in H,0, and freeze~dried. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for C3,4Hg4N405SCH3S0;H-1.6 H,O0 (MW 771.67): 10 . C, 54.47; H, 7.99; N, 7.26 ~ Found: CC, 54.49; H, 7.88; N, 7.08 ’ EXAMPLE 13
LL /
Q__HN~S02 -PHE-NHCHCO-CAD
CH, C=C-CH, NHCOCH;
A solution of 1.35 g (2.0 mmole) of 6 N-SO,-PHE-NHCHCO-CAD in 40 ml CH,Cl, was cooled in ~~ CH, C=C-CH, NH, nL ice and 250 mg (2.2 mmole) of acetylimidazole added, and the solution allowed to stir at room temperature overnight. The solvent was removed under reduced pressure and the residue
Co taken up in EtOAc, and washed with 1N HCl, H,0, saturated
NaHCO;, and saturated NaCl. Drying over MgSO, and removal of the solvent under reduced pressure gave the crude product which was purified by chromatography on silica gel, eluting with CHCl;/MeOH (98/2). There was obtained 1.23 g of product as a white foam. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for C3sH55N;04S-0.4CHCl; (MW 753.58): . C, 56.42; H, 7.41; N, 9.29
Found: C, 56.14, H, 7.53; N, 9.24 yo A2v i - 49 -
EXAMPLE 14 — +0 N-S0,-PHE-NHCHCO-CAD
CH, C=C-CH, NHCOH
A solution of 1.35 g (2.0 mmole) of 0 'N-SO,PHE-NHCHCO-CAD in 20 ml CH,Cl, was cooled in 7 CH, C= CCH, NH, ice and treated with 0.18 ml (2.0 mmole) of formic-acetic anhydride and 0.3 ml (2.0 mmole) of Et,;N, then allowed to stir at room temperature overnight. The solvent was removed i. 10 under reduced pressure and the residue taken up in EtOAc and washed with 1N HCl, H,0, saturated NaHCO,, and saturated
NaCl. Drying over MgSO, and removal of the solvent under reduced pressure left the crude product which was purified by chromatography on silica gel, eluting with CHCl,;/MeOH (98/2).
There was obtained 1.06 g of product as a white foam. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for C3,H53N505S-0.45CHCl; (MW 745.53):
C, 55.50; H, 7.23; N, 9.39
Found: C, 55.59; H, 7.29; N, 9.19 ‘C20 : EXAMPLE 15
A
O_ N-S02-PHE-NHCHCO-CAD
CH, C=C~-CH, NHCSNHCH, _ , A solution of 1.35 g (2.0 mmole) of 7\ .
Q__N-50; ~PHE-NHCHCO-CAD in 20 ml CH,Cl, was cooled in
CH, C=C~-CH, NH, on ice and treated with 154 mg (2.1 mmole) of methyl isothiocyanate and 0.6 ml (4.2 mmole) of Et;N and stirred at room temperature for three days. The solvent was removed under reduced pressure and the residue taken up in EtOAc and washed with 1N HCl, H,0, saturated NaHCOs, and saturated oo | Jfe3e ov oT - 50 -
NaCl. Drying over MgSO, and removal of the solvent under reduced pressure left the crude product which was purified by chromatography on silica gel, eluting with CHCl,/MeCH (98/2).
There was obtained 810 mg of product as a pale yellow foam.
The structure was confirmed by NMR and mass spectroscopy.
Calcd. for C35HggNg07S,:0.8CHCl,; (MW 823.36):
Cc, 51.66; H, 6.88; N, 10.11
Found: CC, 51.85; H, 6.96; N, 10.08
EXAMPLES 16 AND 17 0 ’
SN
O_ N-S-PHE-NHCH(SET)CO-CAD . 0
A solution of 3.3 g (7.7 mmole) of — 0 N-SO, -PHE-NHCH(SEt)CO,H and 1.08 g (8.08 mmole) of HOBT po in 100 ml CH,Cl, was cooled in ice and 1.67 g (8.08 mmole) of
DCC added, followed by a cold solution of 2.15 g (7.7 mmole)
A of NCH (CH, <_) )CH(OH )CH(OH)CH, CH(CH, ), - HC1 and 1.13 ml (8.08 mmole) of Et;N in 30 ml CH;Cl,. After “ stirring at 22° overnight, the mixture was filtered and evaporated under reduced pressure to an oil. The oil was dissolved in EtOAc and washed with saturated NaCl, 1N citric acid, saturated NaCl, saturated NaHCO; and saturated NaCl. — The organic phase was dried over MgSO, and evaporated to give the crude product as a foam, 5.22 g. Chromatography on silica gel, eluting with EtOAc/CHCl, (50/50) gave the faster eluting isomer as a crystalline solid. The solid was triturated with Et,0 and dried under vacuum, giving a white solid, 1.36 g. The structure was confirmed by NMR and mass } spectroscopy.
Calcd. for C;3,;H;,N40;S, (MW.656.91):
Cc, 56.77; H, 7.84; N, 8.53 . Found: CC, 56.84; H, 7.96; N, 8.49 oo 27° - 51 -
Continued elution from the column gave the slower eluting isomer as a white solid, 1.49 g. The structure was confirmed by NMR and mass spectroscopy. ' Calcd. for C3H52N407S, (MW 656.91):
C, 56.77; H, 7.84; N, 8.53
Found: CC, 56.58; H, 7.93; N, 8.47
EXAMPLE 18 \ 0 N-SO, -PHE~NHCHCO-CAD ~ sl J
A solution of 2.42 g (4.97 mmole) of a .
Co O__N-50,-PHE-NHCHCO, H and 0.7 g (5.22 mmole) of HOBT in — \ 80 ml CH,Cl, and 5 ml DMF was cooled in ice and treated with : 15 1.08 g (5.22 mmole) of DCC followed by a cold solution of _ 1.39 g (4.97 mmole) of HyNCH(CH,~ Y )CH(OH)CH(OH)CH,CH
Co "- (CH3)2+HC1 and 0.73 ml (5.22 mmole) of EtsN in 20 ml CH,Cl,.
After stirring at room temperature overnight, the mixture was filtered and the solvent removed under reduced pressure. The : Co 20 residue was taken up in EtOAc and washed with IN citric acid, he saturated NaCl, saturated NaHCO,, and saturated NaCl. After drying over MgSO,, the solvent was removed under reduced pressure to give 3.7 g of the crude product as a brown solid.
Trituration with Et,0 left 2.3 g of partially purified product.
Chromatography on silica gel, eluting with EtOAc/CHCl; (50/50) gave 2.05 g of the product as a white solid. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for C33H5oN407S;, (MW 710.98): 'C, 55.75; H, 7.09; N, 7.88
Found: CC, 55.95; H, 7.28; N, 7.87
EXAMPLES 19 AND 20 6 'N-50,-PHE-NHCH(OCH, CH=CH, )CO~CAD \_
A solution of 1.91 g (4.47 mmole) of —
O_ N-S02-PHE-NHCH(OCH, CH=CH; ) CO, H and 0.62 g (4.56 mmole) of
HOBT in 40 ml CHCl, and 5 ml DMF was cooled in ice and treated with 0.94 g (4.56 mmole) of DCC, followed by a cold solution of 1.25 g (4.47 mmole) of . HoNCH(CHz <) )CH(OH)CH(OH)CH,CH(CH3 ) -HC1 and 0.63 ml (4.56 mmole) of Et;N in 15 ml CH,Cl,. After stirring at room : 10 temperature overnight, the mixture was filtered and the
LC filtrate evaporated under reduced pressure. The residue was a taken up in EtOAc, filtered, and washed with IN citric acid, saturated NaCl, saturated NaHCO,;, and saturated NaCl. Drying over MgSO, and removal of the solvent under reduced pressure gave 2.8 g of the crude product as a foam. Chromatography on silica gel, eluting with EtOAc/CHCl, (50/50) gave the faster eluting isomer. Trituration with Et,0 gave 0.72 g of the “ product as a white solid. The structure was confirmed by NMR : and mass spectroscopy.
Calcd. for C3,Hg,N403S-0.5H,0 (MW 660.86):
C, 58.16; H, 7.93; N, 8.48 co L Found: C, 57.98; H, 8.05; N, 8.41
Further elution from the column gave the slower eluting isomer which still retained about 10% of the faster eluting isomer. Evaporation of an Et,0 solution gave 0.62 g of the product as a white foam. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for C3,Hg;N40gS-0.5H,0 (MW 660.86):
C, 58.16; H, 7.93; N, 8.48 CL
Found: CC, 58.11; H, 8.08; N, 8.29
PELE oo - 53 -
EXAMPLE 21
BMA-PHE-NHCH(OEt )CO-CAD
A solution of 1.58 g (2.18 mmole) of
Z-BMA-PHE-NHCH(OEt)CO-CAD in 100 ml of EtOH was treated with 0.3 g of 20% Pd/C and the mixture purged with hydrogen for four hours. The mixture was filtered and the solvent removed under reduced pressure. The residue was trituated with Et,0 to give 1.2 g of a white solid. Chromatography on silica gel, eluting with a gradient of 0-15% MeOH in CHCl, gave 0.86 g of the product as a white solid. The structure was confirmed by
NMR and mass spectroscopy.
Calcd. for C3,Hg4N4Og-0.3CHCl, (MW 626.62):
C, 61.91; H, 8.73; N, 8.94
Found: C, 61.86; H, 9.15; N, 9.01
NS
EXAMPLES 22 AND 23 ) 6 N-S0, -PHE-NHCH (SCH, CH=CH, ) CO-CAD ~~ / : - A
O__ NSO, -PHE-NHCH(SCH, CH=CH, )CO;H (2.0 g, 4.51 mmole) ~ and HOBT-H,0 (0.67 g, 4.96 mmole) were dissolved in a mixture of 5 ml DMF and 80 ml CH;Cl,. After cooling to 0°, DCC (1.02 g, 4.96 mmole) and a solution of rncu(ci, ) \ —
CH(OH)CH(OH)CH,CH(CH;3 ), -HC1 (1.36 g, 4.86 mmole) and EtzN (0.7 ml, 4.96 mmole) in 25 ml cold CH,Cl, were added. After stirring overnight at room temperature the mixture was filtered, evaporated under reduced pressure to a gum and redissolved in EtOAc. The solution was washed with IN citric acid, saturated NaCl, saturated NaHCO; and saturated NaCl.
The organic phase was dried over MgSO, and evaporated to a foam, 3.18 g. Chromatography on silica gel, eluting with
CHCl3/EtOAc (60/40) gave the faster eluting isomer as a
. ; . - 54 - crystalline solid, 0.79 g. The structure was confirmed by
NMR and mass spectroscopy.
Calcd. for C,,Hg,N40;S, (MW 668.92): - C, 57.46; H, 7.83; N, 8.37
Found: CC, 57.50; H, 7.92; N, 8.37
Continued elution from the column gave the slower eluting isomer as a white foam, 0.81 g. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for Cy,Hg,N,40,S, (MW 668.92):
C, 57.46; H, 7.83; N, 8.37
Found: C, 57.07; H, 7.72; N, 8.04
EXAMPLES 24 AND 25
BOC~-PHE~-NHCH(SEt )CO-CAD \ — .
A solution of 5.48 g (14.3 mmole) of
BOC-PHE-NHCH(SEt)CO,H and 1.97 g (14.6 mmole) of HOBT in 100 ml CH;Cl, and 10 ml DMF was cooled in ice and treated with a cold solution of 4.05 g (14.3 mmole) of
HoNCH(CH, <) )CH(OH)CH(OH)CH,CH(CH; ), -HC1 and 2.0 ml - (14.6 mmole) of EtiN in 70 ml CH,;Cl,, followed by 3.0 g (14.6 mmole) of DCC. After stirring at room temperature overnight, the mixture was filtered and the solvent removed under reduced pressure. The residue was taken up in EtOAc, ~ filtered, and extracted with 1N citric acid, saturated NaCl, saturated NaHCO3, and saturated NaCl. After drying over
Mgso,, the solvent was removed under reduced pressure leaving 8.57 g of the crude product. Chromatography on silica gel, eluting with CHCl3/EtOAc (75/25) gave the faster eluting : isomer. Recrystallization from Et,0/hexane gave 2.26 g of the product as a white solid. The structure was confirmed by :
NMR and mass spectroscopy.
~ | ofoae ) | . es
Calcd. for C3,H53N30¢S (MW 607.85):
C, 63.23; H, 8.79; N, 6.91
Found: CC, 63.34; H, 9.03; N, 6.84
Continued elution from the column gave 2.22 g of the ‘5 slower eluting isomer as a solid. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for C3,Hg3N304S-0.5H,0 (MW 616.87):
C, 62.31; H, 8.82; N, 6.81
Found: CC, 62.41; H, 8.79; N, 6.74
EXAMPLE 26 : 6 N-50, - PHE-NHCH(CH, CN ) CO-CAD ef
A solution of 1.57 g (5.0 mmole) of \ IN , Lo ~~ Q__N-S02-PHE in 25 ml DMF was cooled in ice and treated with 0.67 g (5.0 mmole) HOBT and 1.03 g (5.0 mmole) of DCC.
To this was then added a solution of 1.9 g (5.5 mmole) of
H;NCH(CH,CN)CO~-CAD in 15 ml DMF and the solution stirred at room temperature overnight. The mixture was filtered and the solvent removed in vacuo. The residue was taken up in EtOAc - and washed with 1N citric acid, saturated NaHCO3, and saturated NaCl. Drying over MgSO, and removal of the solvent under reduced pressure gave the crude product. . Chromatography on silica gel, eluting with CHCl;/MeOH (95/5)
Po gave 1.9 g of the product as a white foam, mp 203-204.5°.
Calcd. for C3;H49N50,S:0.25CHCl; (MW 665.59):
C, 56.39; H, 7.46; N, 10.52
Found: CC, 56.12; H, 7.46; N, 10.34
EXAMPLE 27
Vana 0 ,N=S80,~PHE-NHCH(OEt ) CO-CAH
A solution of 0.77 g (1.85 mmole) of / 0 N-S0O,~PHE-NHCH(OEt )CO,H, 0.28 g (2.04 mmole) of HOBT, 0.5 g (1.85 mmole) of H,NCH{ { > JCH({OH)CH(OH)CH,CH(CH,),-HC1 and 0.21 ml (2.04 mmole) of EtizN in 25 ml DMF was cooled in
CL ice and treated with 0.42 g (2.0 mmole) of DCC. After 0.5 hour at 0°, the mixture was allowed to stir at room temperature for 24 hours. The mixture was filtered and the residue washed with CH,Cl,. The combined organic phases were
Co washed with H,0, saturated NaHCOgz, and saturated NaCl.
Drying and removal of the solvent under reduced pressure gave the crude product. Chromatography on silica gel, eluting with a gradient 0-2% MEOH in CHCl, separated the two diastereomers present. There was obtained 70 mg of the pure faster eluting diastereomer.
Calcd. for CyoHgoN4OgS-0.8CHCl,; (MW 722.24): - : C, 51.22; H, 7.09; N, 7.76
Found: C, 51.27; H, 7.93; N, 7.22
EXAMPLE 28 \
TN
HN N-SO,-PHE-NHCH(CO,CHg4) CO-CAD n_/ . SN
A solution of 2.3 g (2.9 mmole) of Z-N N-S0,-PHE- 7
NHCH(CO,CH3)CO-CAD in 50 ml MeOH was treated with 0.25 g of 10% Pd/C and stirred in a hydrogen atmosphere for two hours.
The mixture was filtered through Celite and the filtrate concentrated under reduced pressure to yield 1.9 g of the product. The structure was confirmed by NMR spectroscopy.
o/jo3 0 i - 57 =
The material was converted to the acetate salt and freeze-dried.
Calcd. for C31Hs 1 NgOgS+CyH, 05°1.38H,0 (MW 738.67):
C, 53.65; H, 7.88; N, 9.48
Found: CC, 53.44; H, 7.51; N, 9.41
EXAMPLE 29
STN
CHzN N=-SO,-NHCH(CO,CHj )CO~CAD
No . /\ .
A solution of 1.1 g (1.7 mmole) of HN N-S0, ~PHE~ _
NHCH(CO, CH; )CO~CAD in 20 ml EtOH was treated with 0.5 ml (6.0 mmole) of 37% aqueous formaldehyde and 5 ml of formic acid and heated at reflux for three hours. The mixture was diluted wih EtOAc and washed with 10% K,CO, and saturated - NaCl. Drying over MgSO, and removal of the solvent under reduced pressure gave the product as a foam. It was converted to the acetate salt and freeze-dried. The structure was confirmed by NMR and ‘mass spectroscopy.
Calcd. for C32Hg53N50835:0.5C,H405+1.0H,0 {MW 715.83):
Cc, 55.37; H, 8.03; N, 9.78
Found: CC, 55.32; H, 8.01; N, 9.73
EXAMPLE 30
I
O N-SO,-PHE-NHCH(CO,H)CO~-CAD
NN — ann
A solution of 1.2 g (1.8 mmole) of O_ N-SO,-PHE-
NHCH(CO,CH3 )CO-CAD in 30 ml THF was treated with 2.7 ml of 1N : NaOH and stirred at room temperature for 18 hours. The THF oy 25 was removed under reduced pressure and the residue taken up ’ in H,0 and washed with EtOAc. The aqueous layer was brought to pH 2.7 with IN HCl, and the mixture extracted with EtOAc.
Drying over MgSO, and removal of the solvent under reduced
2Fe3 . - 58 - ee pressure gave 1.1 g of the product as a foam. The structure was confirmed by mass spectroscopy.
Calcd. for CaoH4gN40gS*1.0H,0 (MW 658.73):
C, 54.70; H, 7.65; N, 8.51
Found: CC, 54.72; H, 7.62; N, 8.28
EXAMPLE 31 0 N-S0,-PHE-GLY-CAD
A solution of 5.55 g (16.5 mmole) of GLY-CAD-HCl in 60 ml DMF was treated with diisopropylethylamine until basic.
This solution was added to a cold solution of 5.2 g
VA
(16.5 mmole) of © N-SO,-PHE, 2.39 g (17.4 mmole) of HOBT, fod i. and 3.62 g (17.4 mmole) of DCC in 20 ml of DMF. After two hours at 0°, the mixture was stirred at room temperature overnight. The mixture was filtered and the filtrate concentrated under high vacuum. The residue was taken up in
EtOAc and washed with IN citric acid, saturated NaCl, saturated NaHCO,, and saturated NaCl. Drying over Na,SO, and removal of the solvent under reduced pressure gave 9.44 g of - the crude product as a foam. Chromatography on silica gel, eluting with CHC1l,/MeOH (95/5) gave 7.74 g of the product as a solid foam, mp 90-93°. The structure was confirmed by NMR and mass spectroscopy.
Calcd. for C,oH4gN4075-0.37CHCly (MW 641.53):
C, 54.99; H, 7.60; N, 8.73
Found: C, 54.94; H, 7.73; N, 8.62
2 fea ’ - 59 -
EXAMPLE 32
TN
} 0 N~SO,-PHE-LYS(CSNHCH,) -CAD — . CN
A solution of 2.1 g RY ,N-S0,-PHE-LYS (CSNHCH,) and 1.1 g HOBT in 10 ml DMF was cooled to 15° and treated with 0.8 g DCC. The mixture was stirred for 10 minutes at 15° and treated with a solution resulting from the mixing of 1.1 g
NCH (CH, ) )CH(OH)CH(OH)CH,CH(CHy),-HCL, 0.55 ml EtgN and 10 ml CH,Cl,. After stirring for 48 hours at room temperature, the CH,Cl, was removed under reduced pressure - 10 and the solids filtered off. The filtrate was evaporated oo under high vacuum and the residue taken up in CH,Cl, and washed with H,0, pH 7 phosphate buffer, and 5% K,CO,. Drying over MgSO; and removal of the solvent under reduced pressure gave the crude product. Chromatography on silica gel, eluting with CHCl,/MeOH (9/1) gave the product. The : appropriate fractions were combined using CH,Cl, to give 1.8 g of a foam. The structure was confirmed by mass . spectroscopy. ' Calcd. for ChgHgoNgO;S,-0.5CH,Cl, (MW 783.35):
C, 54.43; H, 7.85; N, 10.73 ‘Found: C, 54.30; H, 7.89; N, 10.89
EXAMPLE 33
CH40~ (CH, ) ;NHSO,-PHE-NHCH ( CO,CH, ) CO-CAD
Substitution of CH30-(CH,),NHSO,-PHE-NHCH(CO,CH,)CO,H
I~ for O N-SO,-PHE-NHCH(CO,CH,)CO,H in Example 2 gives the desired product. The structure is confirmed by NMR and mass spectroscopy. /
gfe30 ’ - 60 - : . EXAMPLE 34
ST
0 N-502 -PHE-NHCH(CO, CH, ) CO-CAD
A solution of 314 mg (1.0 mmole) of O N-S0O, -PHE, / 395 mg of H,NCH(CO,CH3)CO-CAD-HCl, and 135 mg (1.0 mmole) of
HOBT in 20 ml DMF is cooled in ice and 0.14 ml (1.0 mmole) of
Et3N added, followed by 207 mg (1.0 mmole) of DCC. After 15 minutes at 0°, the mixture is allowed to stir at room temperature overnight. The mixture is filtered and the solvent removed under high vacuum. The residue is taken up in EtOAc and washed with H,0, IN HCl, saturated NaHCO4, and saturated NaCl. Drying over MgSO, and removal of the solvent
WT under reduced pressure gives the crude product which can be purified by chromatography on silica gel. The structure is \o confirmed by NMR and mass spectroscopy.
INTERMEDIATES FOR
: : EXAMPLES 1-10, 33
Me, NSO, -PHE . : A solution of PHE (3.3 g) in IN NaOH (20 ml) was treated with a solution of N,N-dimethylsulfamyl chloride (2.3 ml) in
THF (20 ml) and stirred vigorously at 25° for three hours.
The reaction mixture was then treated with additional 1N NaOH _. (20 ml) and N,N~dimethylsulfamyl chloride (2.3 ml) and stirred three hours further at 25°. Finally IN NaOH (20 ml) and diethyl ether (80 ml) were added. The mixture was shaken and the aqueous layer was separated and acidified to pH 1 by addition of IN HCl (25 ml). The product was extracted into ethyl acetate, the solution dried over MgsSO,, and evaporated to give a gum which slowly solidified (4.0 g). The structure was confirmed by NMR spectroscopy.
CH,0- (CH, ) , NHSO, ~PHE
Prepared as above, substituting CH30-(CH, ),NHSO,Cl (prepared according to the method of G. Weib and G. Schulze, © Ann. 729, 40 (1969)) for N,N-dimethylsulfamyl chloride. The product is isolated as its dicyclohexylamine salt. /\ o N-SO, ~PHE en
A solution of 66 g (0.4 mole) of PHE in 120 ml of 3.33N
NaOH was treated dropwise over 30 minutes with a solution of 37.1 g (0.2 mole) of morpholinosulfamyl chloride (prepared according to the method of R. Wegler and K. Bodenbennen,
Ann. 624, 25 (1959)) in 80 ml of THF. The solution was stirred at room temperature for six hours, then acidified to
PH 2 with concentrated HCl. The mixture was extracted with
EtOAc. The EtOAc phase was washed with IN HCl, dried over
MgSO4, and evaporated to a solid. Recrystallization from H,0 oo 15 gave 27 g of the pure product, m.p. 157-158°. : Van 0 N-SO,-TYR(OMe) / 3
Prepared as above, substituting TYR(OMe) for PHE. The structure was confirmed by NMR spectroscopy. . : Me,NSO, -TYR(OMe)
Prepared as above, substituting TYR(OMe) for PHE. The product was isolated as its dicyclohexylamine salt, m.p. — 157-159°.
H,NCH(CO, CH, )CO, CH, Ph
Methyl, benzyl isonitroso malonate was prepared from methyl, benzyl malonate (obtained from Aldrich Chemical Co.) by the procedure described in Organic Synthesis, Col. Vol. V, p. 373. The crude product thus obtained was reduced to the title compound by the procedure described in the Journal of the American Chemical Society, Vol. 75, p. 1970, April 20,
. TAG : . - 62 =~ 1953. The crude product was used without further purification in the following step. id BOC-NHCH (CO, CH; ) CO, CH, Ph
Hy NCH(CO,Me )CO,CH, Ph (94 g) was dissolved in ethyl ether . (750 ml) and cooled to 5°. Di-t-butyldicarbonate (91.7 gq) was added and the mixture was held at 4° overnight. The mixture was stripped to an orange oil (135 g). This oil was chromatographed on silica gel, eluting with hexane-ethyl acetate (85:15). The product was recovered as an oil which solidified upon standing (67 g). MS (FAB) 324 (m+l).
H, NCH ( COs CH, )CO, CH, Ph-HC1 , Treatment of BOC-NHCH(CO,CHj)CO,CH,Ph with HCl gas in
CHzCl, over 5 hours afforded the desired hydrochloride salt after concentration under vacuum. The structure was confirmed by NMR and mass spectroscopy. \
Ho NCH( CO, -i-Pr )CO, CH, Ph-HC1
Following the procedures for preparing
H,NCH( CO, CH; )CO, CH, Ph-HC1 but substituting isopropyl benzyl malonate the desired product was prepared. The structure was ‘ 20 confirmed by NMR and mass spectroscopy.
Lo — 0. /— NN
O N-S-PHE-NHCH(CO,CHj )CO,CH, Ph
Nv i oO
To a mixture of morpholinosulfamyl-PHE (3.14 g), HpNCH(CO;CH; )CO,CH,Ph:-HC1 (2.60 g), EtzN (1.53 ml) HOBT-H,O0 (1.42 g) in DMF (50 ml) was added DCC (2.17 g) and the reaction was stirred at 25°- for twenty-four hours. The reaction was filtered and concentrated under vacuum. The residue was dissolved in EtOAc (200 ml) and washed with oo Tab
Lo . —_ 63 - saturated aqueous NaHCO; (100 ml) and three times with water (100 ml). The solution was dried over MgSO, and concentrated to afford the crude product which was purified by flash chromatography on silica gel.
S The following compounds are obtained in an analogous manner :
CH30- (CH, ) ;NHSO,-PHE-NHCH (CO,CH,) CO,CH,Ph , oO
I
0 N-S-NAPHTHYLALA-NHCH(CO,CHy)CO,CH, Ph r
A 1 0
CH, 0
NL, _ N-S-PHE-NHCH(CO,CH;) CO,CH,Ph
CHg4 0 0 /\ i 0 N-S-PHE-NHCH(CO,-i-Pr)CO,CH,Ph , o
Nes : \_ 0
EN
-_N-£-TYR(OMe)-NHCH(CO,CH,) CO,CH,Ph r
CH, 0 : IVA-PHE-NHCH (CO,CH,)CO,CH,Ph , and . 0 0 N-S~TYR (OMe) -NHCH(CO,CH,)CO,CH, Ph. w—/ H 0 \_ a
O_N-S-PHE-NHCH(CO,CH,)COpH
Lo 0
To a solution of morpholinosulfamyl-PHE-
NHCH(CO,CH53)CO,CH,Ph (5.32 g) in 100 ml methanol was added 20% Pd/C (0.53 g). The suspension was stirred under a hydrogen atmosphere for three hours, filtered, and the solvent removed under reduced pressure to afford the product of sufficient purity for use in subsequent reactions.
JIe30 - 64 -
The following compounds are prepared in an analogous manner: — 0 . \ 0 N-S-NAPHTHYLALA-NHCH(CO2 CH, )CO2H ' 0
CH; 0- (CH, ) , NHSO, -PHE-NHCH (CO, CH; CO, H ,
CHj 0 ~ by ~_ N-S-PHE-NHCH(CO, CH; )COzH ,
CH, 0 0
TNA 1 ,
Oo N-5-PHE-NHCH(CO, -1-Pr)CO2H ,
Ne 0 : CHjy 0 ~ _ N-5-TYR(OMe) -NHCH( CO; CHy ) CO, H ,
CH, 0
IVA-PHE-NHCH( CO, CH; )CO,H , and 0 /—\ 1
O N-S~TYR(OMe)-NHCH(CO,CH, )CO,H . ~~ 0 0 o 'N-S-NAPHTHYLALA 0 . : The tetra-n-butyl ammonium salt of napthylalanine (1.82 g) was dissolved in 25 ml of THF and treated with morpholinosulfamyl chloride (0.37 g). The reaction was . stirred for 21 hours at 25°. The suspension was evaporated ~ and partitioned between EtOAc (50 ml) and 1N HCl (50 ml).
The EtOAc layer was separated, and washed twice with 0.5N
NaOH. The combined basic layers were acidified to pH=1-2 and extracted with EtOAc (50 ml), dried over MgSO, and concentrated. The crude product was concentrated three times . from toluene (100 ml) to afford the product as a crisp foam.
The structure was confirmed by NMR spectroscopy.
fez ‘ : - 65 - . 0 ‘aN
O N-S-PHE-NH,
Nl 0 0
AN | ] . . o, MEE (10.0 g) was dissolved in a 1:1 mixture of
CH,Cl, and THF (250 ml total) and cooled to -50°. Then carbonyl diimidazole (5.4 g) was added and the reaction was warmed to -15° over a 3 hour period. Ammonia gas was bubbled into the solution for 1 hour and the reaction was allowed to warm to 20° over a 2 hour period. The reaction was : concentrated to a gel and triturated with an Et,0 and water mixture to afford a solid. The solid was collected, washed with water and Et,0 and dried in vacuo to afford 6.0 g of product. The structure was confirmed by NMR and mass
No spectroscopy. 0 o N-S-PHE-NHCH(OH)CO,H ru 0 0 !
Nl
To 0 N-G-PHE-NH, (5.9 g) in acetone (300 ml) was added
J 0 glyoxylic acid-H,O (3.64 g) and the reaction was heated to reflux for two days. The reaction was then cooled and concentrated and dissolved in EtOAc. The EtOAc layer was _ washed with saturated sodium chloride, and twice with saturated aqueous NaHCO,;. The combined basic layers were acidified to Congo Red with concentrated HCl. The aqueous layer was concentrated and taken up in EtOAc. The solids ~~ 30 were filtered off and the EtOAc layer was washed with brine, 3 dried over MgSO, and concentrated to afford the product {5.27 g) as a white foam. The structure was confirmed by NMR and mass spectroscopy.
Po Jes - 66 - 0 si 0 N-S-PHE-NHCH(OEt)CO,Et —s 0 0 dd } 5 . To O N-S-PHE-NHCH(OH)CO,H (5.11 g) dissolved in EtOH
Nn / It 0 (100 ml) was added concentrated sulfuric acid (1 ml). The ~ reaction was stirred at 25° for five days. It was then concentrated to an oil, dissolved in EtOAc and washed with saturated aqueous NaHCO; and saturated sodium chloride. The
EtOAc layer was dried over MgSO, and concentrated. The residue was purified by flash chromatography on silica gel and the product was isolated. The structure was confirmed by
NMR and mass spectroscopy. . 15 fo} vo 0 ” 0 N-S-PHE-NHCH(OEt)CO,H ~~ / oO 0
Ni , .
To O N-S-PHE-NHCH(OEt) (4.11 g) dissolved in EtOH es : 20 : 0 (50 ml) was added IN NaOH (20 ml). The reaction was stirred 1 hour at 25°C and quenched with IN HCl (23 ml) and concentrated. The residue was dissolved in EtOAc, washed with saturated sodium chloride, dried over MgSO, and concentrated to afford the product (3.77 g) as a white foam. oo The structure was confirmed by NMR and mass spectroscopy.
: J{o3l : . - 67 ~ . INTERMEDIATES FOR EXAMPLES 11 AND 12
BBSP-HIS(TRT)-OCH,
A solution of 10.0 g (0.035 mole) of (+)-BBSP (EP-236,734), 14.47 g (0.035 mole) of HIS(TRT)-OCH;, and 4.75 g (0.035 mole) of HOBT in 250 ml CH,Cl, was cooled in ice and treated with a solution of 7.25 g (0.035 mole) of DCC in 30 ml CHzCl,, then allowed to stir at room temperature for two days. The mixture was filtered, and the filtrate washed with IN citric acid, saturated NaHCO3, and saturated NaCl.
Drying over Na; SO, and removal of the solvent under reduced pressure gave the crude product which was purified on silica gel, eluting with a gradient of 0-2% MeOH in CHCl;. The
LL product was crystallized from Et,0/hexane to give 12.89 g of el oo a pale yellow solid. —
BBSP-HIS(TRT)
A solution of 12.89 g (0.019 mmole) of
BBSP-HIS(TRT)-OCH; in 150 ml dioxane was cooled to 0° and : 19 ml of IN LiOH added, and the solution allowed to stir at room temperature for 16 hours. The solution was concentrated under reduced pressure, acidified with NaHSO,, and extracted : i. with CHCl;. The CHCl; was washed with saturated NaCl and dried over Na; S04. Removal of the solvent under reduced pressure gave 12.2 g of the product as a white solid. The structure was confirmed by NMR and mass spectroscopy.
BBSP-HIS(TRT)-~CAD
A solution of 2.44 g (8.73 mmole) of Bo NCH(CH, <_) )
CH(OH)CH(OH)CH, CH(CHj ), + HCL in 75 ml DMF was cooled in ice and 1.8 ml (12.9 mmole) of Et;N added. The suspension was then treated with 5.8 g (8.73.mmole) of BBSP-HIS(TRT), 1.18 g (8.73 mmole) of HOBT, and 1.8 g (8.73 mmole) of DCC. After 15 minutes at 0°, the mixture was stirred at room temperature g | ofedv . - 68 - overnight. The mixture was filtered and the DMF removed under high vacuum. The residue was taken up in EtOAc and washed with saturated NaHCO;, then with saturated NaCl.
After drying over Na,SO, and removal of the solvent under reduced pressure, the residue was chromatographed on silica gel, eluting with a gradient of 0-0.75% MeOH in CHCl;. There was obtained 1.6 g of the fast moving isomer and 2.2 g of the" slow moving isomer. The structure was confirmed by NMR and mass spectroscopy.
INTERMEDIATES FOR EXAMPLES 13-15
C1CH, C=C-CH, NHBOC
A suspension of 2.89 g (20.6 mmole) of 1 C1CH,C=C-CH,NH, -HC1 in 30 ml of dioxane was cooled in icé and ~~ 4.5 g (20.6 mmole) of di-tert-butyldicarbonate added, followed by 10.4 ml (20.8 mmole) of 2N NaOH. The cooling was oo removed and the solution allowed to stir at room temperature for two hours. The solution was diluted with EtOAc and the layers separated. The EtOAc layer was washed with H,O0, 1N citric acid, H,0, saturated NaHCO3;, and saturated NaCl.
Drying and removal of the solvent under reduced pressure left - 4.2 g of the product. The material was of sufficient purity for use in the following step. - 9 d_ N-50, ~PHE-NHCH(C0,C,H5 ),
A solution of 12.57 g (0.04 mole) of d “N-S0,-PHE,
A
5.4 g (0.04 mole) of HOBT and 8.47 g (0.04 mole) of diethyl aminomalonate-HCl in 200 ml DMF was cooled in ice and 5.€ ml (0.04 mole) of Et;N added, followed by a solution of 8.34 g (0.04 mole) of DCC in 25 ml DMF. After 1/2 hour at 0°, the solution was left stirring at room temperature overnight. The mixture was filtered and the solvent removed under high vacuum. The residue was taken up in EtOAc and washed with IN
CL A403 : - 69 -
HCl, H,0, saturated NaHCO,, and saturated NaCl. Drying over
MgSO, and removal of the solvent under reduced pressure left 18.1 g of the product as a viscous oil. The material was used directly in the next reaction. - VE 0 N-SO0,-PHE-NH-C(CO,C,Hs), wf
CH, C=C~CH, NHBOC
Under nitrogen, a suspension of 3.5 g (72 mmole) of
NaH-mineral oil (50%) was washed free of the mineral oil with
THF, then suspended in 75 ml DMSO. This suspension was ’
Aan ‘. 10 treated dropwise with 17.0 g (36 mmole) of 0 'N-S0, -PHE-
CH(CO,CyHs), in 50 ml DMSO and stirred at room temperature. \_ After stirring for four hours, the dark solution was treated with 7.47 g (36 mmole) of ClCH,C=C-CH,NHBOC and 1.0 g of KI.
After 40 hours, the solution was treated with IN citric acid : 15 and extracted with EtOAc. The EtOAc was washed two times with H,0, then saturated NaCl. Drying over MgSO, and removal } of the solvent under reduced pressure left 22.7 g of a brown oil. Chromatography on silica gel, eluting with CHCl;/MeOH (99/1) gave 14.2 g of product, sufficiently pure to use in _ 20 the following reaction.
NA
O__N-50, ~PHE-NHCHCO, H : (_. CH, C=C~-CH, NHBOC , 7 . A solution of 9.82 g (15.4 mmole) of O N~SO, -PHE- nS
NHC (CO2C2Hs ), in 45 ml dioxane and 45 ml EtOH was treated
CH, C=C-CH, NHBOC with 24 ml (48 mmole) of 2N NaOH and stirred at room temperature overnight. The solvent was removed under reduced pressure and the residue taken up in H,O and washed with
Et,0. The pH was brought to 2.5 with dilute HCl and the mixture extracted twice with EtOAc. The EtOAc was washed
Ce Spl - 70 - with saturated NaCl, dried over MgSO,, and the solvent removed under reduced pressure. The residue was taken up in 100 ml dioxane and 100 ml toluene and heated at reflux for three hours. Removal of the solvent under reduced pressure left 7.8 g of the product as a golden brown foam. The product was sufficiently pure for use in the following step.
FER
0 N~SO; -PHE-NHCHCO-CAD \__/ i
CH, C=C~CH, NHBOC
A solution of 5.65 g (1.05 mmole) of 0 'N-S0,-PHE- : A
Y. 10 NHCHCO,H |, 1.42 g (1.05 mmole) of HOBT and 2.93 g
CH, C=C-CH,; NHBOC (1.05 mmole) of H,NCHCH(OH)CH(OH)CH,CH(CH;), HCl in 50 ml DMF oo : was cooled in ice and 1.48 ml (1.05 mmole) of Etz;N added followed by 2.2 g (1.05 mmole) of DCC in 10 ml DMF. After 15 minutes at 0°, the mixture was stirred at room temperature overnight. The mixture was filtered and the solvent removed under reduced pressure. The residue was taken up in EtOAc . and washed with 1N HCl, H,O, saturated NaHCO,;, and saturated ‘ NaCl. Drying over MgSO, and removing the solvent under reduced pressure gave the crude. product which was purified by chromatography on silica gel, eluting with CHCl;/MeOH (99/1). to There was obtained 5.36 g of pure product as a pale yellow \ foam.
1 B fo | J fo3 ;
SE - 71 - — vo 0 N-SO,; -PHE-NHCHCO-CAD boo
Nn / | i
CH,C=C-CH, NH, : — i
A solution of 5.3 g (6.9 mmole) of O N-SO, -PHE- { ./ f: {
NHCHCO-CAD in 50 ml CH,Cl, was treated with HCl gas i
CH, C=C-CH, NHBOC for five minutes, then stirred at room temperature for 1.5 hours. The solvent was removed under pressure, CH,Cl, added, and the solvent removed again. The residue was taken up in CH;Cl, and treated with cold CH,Cl, that had been saturated with ammonia. The NH4Cl was filtered off, and the - solvent removed under reduced pressure to give 4.05 g of the product as a white solid. \ INTERMEDIATES FOR EXAMPLES 16 AND 17 . Oo N-SO, ~-PHE-NHCH(OH)CO, Et
Nn / ’ .
A solution of 13.0 g (33.5 mmole) of O N-SQO, ~PHE~
J
NHCH(OH)CO;H in 200 ml ab. EtOH was treated with 2 ml concentrated H;SO4 and stirred at room temperature overnight. - Evaporation under reduced pressure gave a syrup which was taken up in EtOAc and washed with saturated NaCl, saturated
NaHCO; , 1N citric acid, and saturated NaCl. Drying over
U " MgSO4 and removal of the solvent under reduced pressure gave : thé crude product. Chromatography on silica gel, eluting with EtOAc/CHCl; (50/50) gave 8.75 g of the product as a white foam. The structure was confirmed by NMR and mass spectroscopy. ' / : oO N-SO, -PHE~NHCH(SEt)CO,Et
Nn / 7
A solution of 4.4 g (10.0 mmole) of O N-SO,-PHE-
NHCH(OH)CO,Et in 50 ml CH,Cl, was treated with 2.6 ml
Co | ZEEE
I
- 72 - {29 mmole) of EtSH and 0.15 g of anhydrous 2-naphthalene- sulfonic acid and heated at reflux for two hours. The mixture was filtered and the filtrate evaporated to an oil. i
The oil was taken up in EtOAc and washed with saturated :
NaHCO;, saturated NaCl, 1N citric acid, and saturated NaCl. !
Drying over MgSO, and removal of the solvent under reduced pressure gave the crude product as a foam. Chromatography on silica gel, eluting with CHCl,/EtOAc (60/40) gave 3.83 g of : the product as a glass. The structure was confirmed by NMR and mass spectroscopy. ~~ : : ; “ oO N-SO, ~PHE-NHCH(SEt)CO.H
LY ~~
TN
A solution of 3.54 g (7.7 mmole) of Q_ _N-SO;-PHE- \ NHCH(SEt)COzEt in 25 ml dioxane was treated with 15.4 ml of
IN NaOH and stirred for 45 minutes, then treated with 7.7 ml of 1N HCl. The solvent was removed under reduced pressure, an additional 7.7 ml 1N HCl added, and the material taken up in EtOAc. The EtOAc was washed with saturated NaCl, dried : over MgSO,, and the solvent removed under reduced pressure to give 3.37 g of the product as a foam. The structure was ¢c 20 confirmed by NMR and mass spectroscopy. The material was
L used without further purification.
INTERMEDIATE FOR EXAMPLE 18
Co am
O_ N-50, I H ay 7 \
A solution of 4.07 g (10.5 mmole) of O_ N-S0z-PHE-
BS NHCH(OH)CO,H and 2.4 ml of 2-mercaptothiophene in 50 ml HOAc : © was cooled in ice and 5 ml concentrated H,SO, added over a ; two minute period. After stirring at room temperature overnight, the solvent was evaporated under reduced pressure.
; pie’
L. , {03 “ =, | i - 73 - A ne a 3
Water was added, and the gummy precipitate taken up in Et,0. *
The Et,0 phase was washed with H,0, then saturated NaCl. The :
Et,0 was then extracted with saturated NaHCO;, and the NaHCO; 5 extract acidified with concentrated HCl, and then extracted with EtOAc/Et,0 (75/25). The organic phase was then washed with saturatred NaCl and dried over MgSO,. Removal of the solvent under reduced pressure gave 4.54 g of the crude product as a tan solid. Chromatography on silica gel, eluting with EtOAc/CHCls/MeOH (45/45/10) gave 2.61 ml of the product as a pale yellow foam. The structure was confirmed by NMR and mass spectroscopy. - INTERMEDIATES FOR EXAMPLES 19 AND 20 : O N-S0,-PHE-NHCH(OCH, CH=CH, )CO, CH, CH=CH,
Co / o .
A solution of 3.0 g (7.74 mmole) of © N-SO, ~PHE~ nf
NHCH(OH)COyH in 100 ml allyl alcohol was treated with 1 ml concentrated H,SO, and stirred at room temperature overnight.
The mixture was evaporated to an oil, taken up in EtOAc, and washed with saturated NaCl, saturated NaHCO3;, 1N citric acid, . and saturated NaCl. Drying over MgSO, and removal of the ~ 20 solvent under reduced pressure gave 4.55 g of the crude product as an oil. Chromatography on silica gel, eluting } with hexane/EtOAc (70/30) gave 2.52 g of the pure product as
LU an oil. The structure was confirmed by NMR and mass spectroscopy.
TN o N-SO, -PHE-NHCH(OCH, CH=CH, )CO,H —/ . J
A solution of 2.52 g (5.39 mmole) of O N-SO, -PHE-
NHCH(OCH, CH=CH, )CO,CH,CH=CH, in 25 ml dioxane was treated with 10.8 ml of IN NaOH and stirred for one hour, then treated with 5.4 ml of IN HCl and the mixture evaporated under reduced pressure to an oil. The oil was suspended in
Y
Lo 2a ; : - 74 -
EtOAc/Et,0 (75/25), 5.4 ml of IN HCl added, and the solution washed with saturated NaCl. Drying over MgSO, and removal of the solvent under reduced pressure left 2.05 g of the product as a foam. The structure was confirmed by NMR and mass spectroscopy. The material was used without further purification.
INTERMEDIATES FOR EXAMPLE 21
Z2-BMA-PHE-OMe . A solution of 6.28 g (25.0 mmole) of Z-p-aminoisovaleric “10 acid (J. Chem. Soc. 2001 (1973)) and 3.45 g (25.5 mmole) of
HOBT in 150 ml CH,Cl, was cooled in ice and a suspension of 5.39 g (25.0 mmole) of PHE-OMe-HCl and 3.55 ml (25.5 mmole) \ of EtgN in 100 ml of cold CH,Cl, added, giving solution. The solution was treated with 5.26 g (25.5 mmole) of DCC and stirred at room temperature overnight. The mixture was filtered and the solvent removed under reduced pressure. The
Pesidue was taken up in EtOAc and washed with IN citric acid, saturated NaCl, sataurated NaHCO3, and saturated NaCl. After drying over MgSO, the solvent was removed under reduced ’ 20 pressure to give 11.38 g of the crude product. ~ ~ Chromatography on silica gel, eluting with hexane/EtOAc (70/30) gave 9.65 g of the product as a viscous oil. The structure was confirmed by NMR and mass spectroscopy. — Z~BMA-PHE-NH,
Z-BMA-PHE~OMe (4.74 g, 115 mmole) was dissolved in 100 ml MeOH at -40° and saturated with anhydrous NH, gas. ~ After stiiring at room temperature for two hours, the mixture was evaporated under reduced pressure to a foam, 4.49 g. The structure was confirmed by NMR and mass spectroscopy. The material was used in the following step without further purification.
y
Lo 21°3¢ oo - 75 = : !
Z-BMA-PHE-NHCH (OH) CO, H
A solution of 4.35 g (10.9 mmole) of Z-BMA-PHE-NH, and 1.21 g (13 mmole) of glyoxylic acid-H,0 in 75 ml acetone was heated at reflux for 18 hours. An additional 1.0 g of i glyoxylic'H,0 was added and the refluxing continued for 24 hours. An additional 0.5 g of glyoxylic acid:-H,0 was then added and the solution refluxed an additional 24 hours. The solvent was then removed under reduced pressure and the residue taken up in EtOAc. The EtOAc was washed with saturated NaCl, saturated NaHCO,, saturated NaCl, 1N citric “ acid, and saturated NaCl. After drying over MgSO, and removal of the solvent under reduced pressure, there was - obtained 4.86 g of the crude product. Trituration with Et,0 gave 2.99 g of the product as a white foam. The structure oo 15 was confirmed by mass spectroscopy. The material was used in the next step without further purification.
Z-BMA-PHE-NHCH(OEt )CO,Et : A solution of 2.95 g (6.26 mmole) of Z-BMA-PHE-
NHCH(OH)CO,H in 25 ml ab. EtOH was treated with 0.5 ml ’ \ 20 concentrated H;SO, and stirred at room temperature overnight. ’ The solvent was removed and the residue taken up in EtOAc and washed with saturated NaCl, saturated NaHCO5;, saturated NaCl,
IN citric acid, and saturated NaCl. After drying over MgSO,, : the solvent was removed under reduced pressure. The residue was twice resubjected to the reaction conditions until the reaction had gone to completion. The crude product was chromatographed on silica gel, eluting with EtOAc/CHC1;, (50/50), then rechromatographed, eluting with hexane/EtOAc (75/25). There was obtained 2.46 g of the product. The structure was confirmed by NMR and mass spectroscopy.
toe 2036 ’ - 76 =
Z-BMA-PHE-NHCH(OEt )CO,H
A solution of 2.46 g (4.66 mmole) of Z-BMA-PHE-
NHCH(OEt)CO,Et in 60 ml dioxane was treated with 9.3 ml of 1N
NaOH and stirred at room temperature for one hour, then treated with 4.66 ml of 1N HCl and the solvent removed under reduced pressure. An additional 4.66 ml of 1N HCl was added and the residue taken up in EtOAc and washed with saturated
NaCl. After drying over MgSO, the solvent was removed under reduced pressure to give 1.31 g of the product as a white foam. The structure was confirmed by mass spectroscopy. - Z-BMA-PHE-NHCH(OEt )CO-CAD
A solution of 1.31 g (2.91 mmole) of Z-BMA-PHE-
NE NHCH(OEt)CO,H and 0.4 g (2.97 mmole) of HOBT in 50 ml CH,;Cl, and 4 ml DMF was cooled in ice and treated 0.62 g (2.97 mmole) of DCC followed by a cold solution of 0.82 g (2.91 mmole) of A NCH (cH, )CH(OH)CH(OH)CH, CH(CH, ), - HCl and 0.42 ml (2.97 mmole) of Et3;N in 20 ml CH,Cl,. After 3 stirring overnight at room temperature, the mixture was . filtered and the solvent removed under reduced pressure. The © Y © 20 residue was taken up in EtOAc, filtered, and washed with 1N citric acid, saturated NaCl, saturated NaHCO;, and saturated
NaCl. Drying over MgSO, and removal of the solvent under
L reduced pressure gave the crude product. Chromatography on ’ silica gel, eluting with CHCl,/EtOAc (75/25) gave 1.58 g of the product as a white foam.
INTERMEDIATE FOR EXAMPLES 22 AND 23 0 W-S0, -PHE-NHCH(SCH, CH=CH, ) CO, H
A;
A solution of 17.4 g (44.9 mmole) of 0 N-50,-PHE- ’ /
NHCH(OH)CO,H in 250 ml HOAc was cooled in ice and 20.6 ml
} . . F034 ; : : - 77 - (181 mmole) of 70% allyl mercaptan added, followed by 15 ml of concentrated HySO4. The mixture was stirred at room temperature overnight and the solvent then removed under reduced pressure. The residue was mixed with ice and ; 5 extracted with Et,0. The Et,0 was washed with saturated
NaCl, then saturated NaHCO;. The NaHCO; wash was brought to . pH 1 with concentrated HCl and extracted with Et,0. The Et,0 was washed with saturated NaCl. Drying over MgSO, and removal of the Et,0 under reduced pressure left the crude product. Chromatography on silica gel, eluting with
CHCl; /MeOH (96/4) gave the product. Crystallization from
EtOAc/isopropyl ether gave 4.0 g of a solid. The structure . was confirmed by NMR and mass spectroscopy.
INTERMEDIATES FOR EXAMPLES 24 AND 25 ’
BOC-GLY-OCH, CCl,
A solution of 26.28 g (0.15 mole) of BOC-GLY and 27 ¢ oo (0.18 mole) of 2,2,2-trichloroethanol in 250 ml CH,Cl, was cooled in ice and 0.18 g of 4-dimethylaminopyridine added, : followed by 31.6 g (0.153 mole) of DCC. After stirring at . 20 room tempeerature for 3.5 hour, the mixture was filtered and \_ the solvent removed under reduced pressure. The residue was taken up in EtOAc and washed with 1N citric acid, saturated
NaCl, saturated NaHCO,, and saturated NaCl. Drying over [ MgSO, and removal of the solvent under reduced pressure left — 25 the crude product. Chromatography on silica gel, eluting with hexane/EtOAc (90/10) gave 45.0 g of the product as a crystalline solid. = The structure was confirmed by NMR and mass spectroscopy.
BOC-NHCH (Br )CO, CH, CCl, - 30 BOC-GLY-OCH,CCls (22.5 g, 73.3 mmole) and
N-bromosuccinimide (22.5 gq, 73.4 mmole) was added to 300 ml
CCl, in a quartz reaction flask illuminated by a Corex-
Co #
Co : 2fed E - 78 -
L filtered 450 watt Hanovia mercury lamp and irradiated for one h hour at 40°. The succinimide was filtered off and the r filtrate was evaporated to a white, crystalline solid : 26.85 g. The structure was confirmed by NMR. The material was used without further purification in the following ! reaction.
BOC~-NHCH(SEt )CO, CH, CCl,
A suspension of 1.2 g (25 mmole) of NaH-mineral oil (50%) was washed free of mineral oil with THF, then resuspended in 100 ml of THF, and treated with 2.15 ml o (29 mmole) of ethanethiol. After one hour at room temperature, the suspension was cooled to 0° and a solution of 9.46 g (25 mmole) of BOC-NHCH(Br)CO,CH,CCl; in 50 ml THF \_ was added over 15 minutes, and the mixture left stirring at room temperature overnight. The solvent was removed under Co : reduced pressure and the residue taken up in EtOAc and washed with IN citric acid, saturated NaCl, saturated NaHCO, and : saturated NaCl. Drying over MgSO, and removal of the solvent under reduced pressure left 7.11 g of the crude product as a red oil. Chromatography on silica gel, eluting with ‘hexane/EtOAc (70/30) gave 7.56 g of the product as a yellow ’ “ oil. The structure was confirmed by NMR and mass spectroscopy. Some replacement of the trichloroethyl group by ethanethiol had occurred. The crude material was used in the following reaction. : ’
H,NCH(SEt)C0,CH,CCl,-HC1
BOC-NHCH(SEt)CO,CH,CCly (7.04 g, 19.2 mmole) was dissolved in 200 ml CH,Cl, and occasionally purged with anhydrous HCl gas over five hours. After standing at room temperature overnight, the mixture was filtered and evaporated under reduced pressure to an orange oil. } : Trituration with Et,0 gave an orange syrup, 5.47 g. The structure was confirmed by NMR, which also showed the
Co 2493C ¢ ’ - 79 - : presence of some HyNCH(SEt)COSEt-HCl. The crude material was 3 used in the following reaction without further purification.
BOC-PHE~NHCH (SEt )CO, CH, CCl,
A solution of 4.71 g (17.7 mmole) of BOC-PHE, 2.47 g (18.3 mmole) of HOBT, and 5.38 g (17.7 mmole) of
H;NCH(SEt)CO,CH,CCl3-HC1 in 125 ml CH,Cl, was cooled in ice and 3.78 g (18.3 mmole) of DCC was added, followed by 4.1 ml (28.9 mmole) of EtzN. After stirring at room temperature overnight, the mixture was filtered and the solvent removed under reduced pressure. The residue was taken up in EtOAc,
LO filtered, and washed with 1N citric acid, saturated NaCl, saturated NaHCO;, and saturated NaCl. Drying over MgSO, treating with charcoal, and removal of the solvent under \_ reduced pressure gave 9.43 g of the crude product as a dark red oil. Chromatography on silica gel, eluting with hexane/EtOAc (80/20) gave 6.08 g of the product as a white . foam. The structure was confirmed by NMR and mass - spectroscopy, which also showed: the presence of some
BOC~PHE-NHCH(SEt)COSEt. The material was used in the next . 20 reaction without further purification. _ BOC-PHE~-NHCH(SEt)CO,H : A solution of 5.89 g (11.5 mmole) of BOC-PHE-
WU NHCH(SEt)CO,CH,CCl; in 25 ml dioxane was treated with 20 ml of IN NaOH and stirred for two hours. The solution was then
Bh 25 treated with 12 ml of IN HCl and the solvent evaporated. The residue was taken up in EtOAc and 12 ml of IN HCl. The organic phase was washed with saturated NaCl and dried over
MgsO,. Removal of the solvent under reduced pressure gave 5.96 g of the product as a foam. The structure was confirmed by NMR and mass spectroscopy.
CL 9Fo3¢ : - 80 - :
INTERMEDIATES FOR EXAMPLE 26 7~NHCH (CH, CN) CO, H
A solution of 33.6 g (0.126 mole) of Z-ASN in 250 ml pyridine was treated with 27.5 g (0.133 mole) of DCC and stirred at room temperature overnight. The mixture was filtered and the filtrate evaporated. The residue was taken up in H,0, filtered, and the pH brought to 2 with dilute
HCl. After cooling overnight, the product was collected and recrystallized from 1,2-dichloroethane to give 20.6 g of product.
LO
2~NHCH ( CH, CN ) CO~CAD \_ A solution of 1.78 g (7.2 mmole) of Z-NHCH(CH,CN)CD.H and 0.97 g (7.3 mmole) of HOBT in 50 ml of CHCl, was cooled in ice and treated with 1.48 g (7.3 mmole) of DCC, followed : 15 by a solution of 2.0 g (7.2 mmole) of ncn (ch{_) )
CH (OH )CH(OH) CH, CH(CHg )2 HCL and 0.93 g (7.5 mmole) of - diisopropylethylamine in 20 ml CH,Cl,. After two hours at he 0°, the solution was stirred at room temperature overnight.
The mixture was filtered and the filtrate washed with 1N citric acid, saturated NaHCO;, and saturated NaCl. Drying over MgSO, and removal of the solvent under reduced pressure - left a white solid. Recrystallization from EtOAc provided 2.6 g of the pure product.
H, NCH( CH, CN )CO-CAD
A solution of 2.6 g (5.5 mmole) of Z~NHCH(CH;CN)CO-CAD in 30 ml MeOH was treated with 0.4 g of 5% Pd/C and stirred in a hydrogen atmosphere for 2.5 hours. The mixture was filtered and the filtrate evaporated in vacuo to give 1.9 g of the product as a foam.
! F : . Ho3te : ' - 81 -
INTERMEDIATES FOR EXAMPLE 27 ;
BOC-CYCLOHEXYLGLYCINE i
A solution of 94.4 g (2.66 mole) of BOC-phenylglycine in 1 1 of 2-propanol was treated with 5 g of 10% Rh/C and reduced at 25°, 50 psi. The mixture was filtered and the : solvent removed under reduced pressure. The product was used without further purification.
BOC-NHCHCO-N( CH; ) OCH; : v 0 ; A solution of 102 g (0.4 mole) of BOC-cyclohexylglycine
NS 10 in 600 ml CH;Cl, was cooled to -50° and 58.4 ml (0.48 mole) of N-methylpiperidine added followed by 42 ml (0.44 mole) of ethyl chloroformate. This solution was added dropwise : , to a solution of 42.5 g (0.44 mole) of
O,N~dimethylhydroxtylamine-HCl and 58.4 ml (0.4 mole) of oo 15 N-methylpiperidine in 200 ml CH,Cl,. After 30 minutes the mixture was washed with 10% citric acid, saturated NaHCOj, . and saturated NaCl. After drying, the solution was filtered h_ through silica gel, and the solvent removed under reduced pressure. There was obtained 87.6 g of the product. The 20 structure was confirmed by NMR spectroscopy. :
BOC~-CYCLOHEXYLGLYCINAL
A solution of 40 g (0.119 mole) of BOC-
CYCLOHEXYLGLYCINE, O,N-DIMETHYLHYDROXAMIDE in 550 ml Et,0 was oo cooled in ice and 148 ml (0.148 mole) of a 1M solution of 25 LiAlH4 in Et,0 added over 0.5 hour. After an additional minutes, the mixture was treated cautiously with 28 g of
KHSO4 in 100 ml H,0. The mixture was filtered through Celite and washed with 10% citric acid and saturated NaHCO,;. After drying the solvent was removed under reduced pressure to give co : g103¢
Co - 82 - the crude BOC-CYCLOHEXYLGLYCINAL. The material was used immediately in the following reaction.
BOC-NHCHCH=CHCH,CH(CHg),
A
To a suspension of 23.8 g (0.19 mole) of KH (as a 35% suspension in mineral oil) in 100 ml DMSO at -5° was added dropwise over one hour, 42.1 ml (0.199 mole) of hexamethyldisilazane. This was then treated with 78.35 g “ (0.19 mole) of the triphenylphosphonium salt derived from isovaleryl bromide. After cooling to -78°, the mixture was treated with 23 g (0.095 mole) of BOC-CYCLOHEXYLGYCINAL in \_ 100 ml of toluene. After stirring at room temperature overnight, the mixture was washed with H,0, saturated NaCl, i and saturated NaHCO,. Drying and removal of the solvent under reduced pressure gave the crude product. . 15 Chromatography on silical gel, eluting with CHCl;/hexane . (80/20) gave 19 g of the product. The structure was confirmed by NMR spectroscopy. : _ IE (CHjy)» oo
A solution of 5.25 g (18.0 mmole) of “yg
CHCH,CH(CHz), in 100 ml THF was treated with 6.0 g (44 mmole) : of 4-methylmorpholine, N-oxide and 0.05 g (0.18 mmole) of . osmium tetroxide and the mixture stirred at room temperature for four days. The THF was then removed under reduced pressure and the residue taken up in EtOAc and washed with 10%
Na,SO,, 10% citric acid, saturated NaHCO, and saturated NaCl.
Drying and removal of the solvent under reduced pressure gave
M oo get - 83 - i the crude product. The desired diastereomer could be isolated by chromatography on silica gel, eluting a gradient of 10-30%
EtOAc in hexane. There was obtained 1.87 g of product.
H, NCHCH (OH) CH (OH )CH, CH( CH, ), - HC1
A solution of 1.87 g (5.71 mmole) of
BOC-NHCHCH(OH)CH(OH)CH,CH(CH; ), in 50 ml of 2N HCl in MeOH “ " was allowed to stand overnight. Removal of the solvent under reduced pressure left 1.5 g of the product. The structure _ was confirmed by NMR spectroscopy. . 10 INTERMEDIATES FOR EXAMPLE 28 : : Z-N N-SO,-PHE
L-Phenylalanine (1.65 g) was converted to its . tetramethyl ammonium salt and dissolved: in a mixture
A of THF (50 ml) and 2-propanol (12 ml). 4-Carbobenzyloxy- piperazinosulfamyl chloride (1.59 g) was added and the reaction was stirred for 16 hours in a stoppered flask. The \_ resulting suspension was evaporated and the residue was - partitioned between dichloromethane and IN HCl. The organic layer was washed with 1N HCl then extracted with 0.3N NaOH.
The basic extract was immediately acidified to pH 1 with concentrated HCl and extracted with ethyl acetate. This extract was dried over magnesium sulfate and evaporated to give the desired product as an off-white solid (1.35 g). The structure was confirmed by NMR spectroscopy.
i
FC IPB
- 84 -
BOC-AMINOMALONIC ACID, METHYLESTER
To a solution of 16.17 g (13.5 mmole) of BOC-amino- malonic acid, methyl benzyl ester in 250 ml MeOH was added 0.66 g of 20% Pd/C catalyst. The suspension was purged with hydrogen gas for 1.5 hours, after which the suspension was filtered and the solvent removed under reduced pressure at 30°, giving a syrup, 12.5 g. The product was kept at 4° until used in the following reaction.
BOC-NHCH (CO, CH ) CO~CAD - 10 A solution of 2.2 g (9.4 mmole) of BOC-aminomalonic acid, methyl ester, 1.34 g (9.9 mmole) of HOBT, 2.89 g \ (10 mmole) of npnen(on, )CH(OH)CH(OH)CH,CH(CHg ), *HC1, : and 1.5 ml (10 mmole) of EtsN in 100 ml CH,Cl, was cooled in ice and treated with 2.04 g (9.9 mmole) of DCC in 100 ml of 4 ’ 15 CH,Cl,. After 0.5 hour at 0°, the mixture was allowed to stir at room temperature for 24 hours. The mixture was filtered and washed with H,0, saturated NaHCO;, and saturated
CF NaCl. Drying and removal of the solvent under reduced ~ pressure gave the crude product. Chromatography on silica gel, eluting with CH,Cl,/MeOH (9/1) gave 2.2 g of product.
The structure was confirmed by NMR and mass spectroscopy.
H, NCH (CO, CH, )CO-CAD- HC1
A solution of 6.25 g (14 mmole) of BOC-NHCH(CO,CHj3 )CO-CAD in 65 ml of 2.3M HCl in MeOH was stirred at room temperature : 25 overnight. The solvent was removed under reduced pressure giving the product. The structure was confirmed by NMR and mass spectroscopy. The product was used in the next reaction : ". without further purification.
“r oo
SN SER ope : . - BS - i [TN
Z-N N-S0,-PHE~NHCH(CO, CH; )CO-CAD : rt
FARR
A solution of 2.36 g (5.3 mmole) of Z-N N-502-PHE,
Nee 0.72 g (5.3 mmole) of HOBT, 1.99 g (5.0 mmole) of
NCH (cH, <) )CH(OH)CH(OH)CH,CH (CH; ),-HC1, and 0.74 ml (5.3 mmole) of EtzN in 60 ml CH,Cl, was cooled in ice and treated with 1.09 g (5.3 mmole) of DCC in 10 ml CH,Cl,.
After 0.5 hour at 0°, the mixture was allowed to stir at room temperature for 48 hours. The mixture was filtered, and the “ filtrate washed with H,0, saturated NaHCOz, and saturated
NaCl. Drying and removal of the solvent under reduced pressure gave the crude product. Chromatography on silica \_ gel, eluting with CH;Cl,/MeOH (9/1) gave 2.5 g of the product. The structure was confirmed by NMR and mass ; spectroscopy. . 15 INTERMEDIATES FOR‘ EXAMPLE 31
BOC~GLY-CAD
S A solution of 2.66 g (15.2 mmole) of BOC-GLY, 2.2 g¢ (15.9 mmole) of HOBT, 4.25 g (15.2 mmole of _ H,NCH(CH;< ) )CH(OH)CH(OH)CH,CH(CHj),+HCl, and 2.16 ml (15.5 mmole) of EtzN in 40 ml DMF was cooled in ice and treated with 3.32 g (15.9 mmole) of DCC in 5 ml DMF. After two hours at 0°, the mixture was allowed to stir at room temperature for 24 hours. The mixture was filtered and the : filtrate concentrated under high vacuum. The residue was taken up in EtOAc and washed with H,0, 1N citric acid, oo saturated NaHCO, and saturated NaCl. Drying and removal of the solvent under reduced pressure gave the crude product.
Chromatography on silica gel, eluting with CHCl;/MeOH od
, — C—O RMA —- an —_— 3 ] , ’ ' ' 9 P 2 b ; - 86 - (97.5/2.5) gave 6.6 g of the product. The structure was confirmed by NMR and mass spectroscopy.
GLY-CAD-HC1
A solution of 6.62 @ (16.5 mmole) of BOC-GLY-CAD in 60 ml CHCl, was treated with 30 ml of TFA and stirred at room temperature for two hours. The solvent was removed under reduced pressure; CH,Cl, added, and the solvent removed again. The residue was then taken up in CH,Cl, and HCl gas bubbled in. removal of the solvent under reduced pressure wo 10 gave the product. The material was used in the next reaction without further purification. ( - INTERMEDIATES FOR EXAMPLE 32 /mN 0, N-80,-PHE-LYS (2) ~0CHa } A mixture of No (4-morpholinosulfonyl) “PHE {3.15 gr 10 mmole), DCC (2.1 g, 10 mmole), HOBT (1.3 dv 10 mmole) and
DMF (20 ml) was atirred at 20° for five minutes. The » resulting slurry was treated consecutively with : | LYS (2)-OCH, HCl (3.32 g, 10 mmole), EtgN (1.4 ml, 10 mmole) = and CH,Cl, (10 ml). The reaction was stirred for 48 hours at 20° then CHpClp was evaporated. Ethyl acetate was added and
U the solids were removed by filtration. Evaporation of the oo filtrate gave a wet solid that was triturated with water, dissolved in CHCl, and washed with 5% K,CO3- The organic layer was dried over MgSO, and evaporated to a pale yellow solid. Trituration with ethyl acetate gave 5.3 gq of a : colorless solid. : Van 0, N-§0, ~PHE-LYS (CSNHCHg) “OCH: cand
SY
A solution of O K-50, -PHE-LYS (2) ~0CHa (5.28 gv lt
; Coe : oe3© Cy ’ - 87 - : 8.95 mmole) in THF (125 ml) was treated with 20% Pd/C (0.55 g) and stirred under an atmosphere of hydrogen. After three hours, methanol (125 ml) was added and catalyst removed by filtration. The resulting solution was treated with methyl isothiocyanate (0.7 g, 9.6 mmole) and stirred 18 hours at 20°. Evaporation gave a solid that was recrystallized from hot CHCl; by dropwise addition of ether to give the desired product (4.25 g). The structure was confirmed by mass spectroscopy.
SN . oO N-5S0, -PHE-LYS (CSNHCH;, ) : n_/ : } ST - A solution of 4.25 g (8.2 mmole) of 0 N-SO, -PHE~-
LYS(CSNHCH3 )-OCH3 in 50 ml THF was treated with 20 ml of IN
LL NaOH and stirred at room temperature for 24 hours. The solution was diluted with H,0 and the pH brought to two with ] 15 2N HCl. The solution was extracted with CH,Cl,. Drying the organic layer over MgSO, and removal of the solvent under . reduced pressute left 3.98 g of the product. The structure was confirmed by mass spectroscopy.
INTERMEDIATES FOR EXAMPLE 34
Che : : 20 BOC-NHCH( CO, CH, compeZeI-Ch CH(CH3), “ J : A solution of 234 mg (1.0 mmole) of BOC-
NHCH(CO,CH3 )CO,H, 210 mg (1.0 mmole) of
Hp NCH(CH,X ) }CH=CH-CH,CH(CH3),, and 135 mg (1.0 mmole) of
HOBT in 15 ml DMF is cooled in ice and 207 mg (1.0 mmole) of } 25 DCC added. After 0.5 hour at 0°, the mixture is allowed to stir at room temperature overnight. The mixture is filtered and the solvent removed under high vacuum. The residue is
CL 220 ! ¢ - 88 - taken up in EtOAc and washed with H,0, IN HCl, saturated
NaHCO3, and saturated NaCl. Drying over MgSO, and removal of the solvent under reduced pressure gives the crude product which can be purified by chromatography on silica gel. The structure is confirmed by NMR and mass spectroscopy. a : BOC-NHCH (CO, CH3 )CO~CAD
A solution of 4.24 g (10 mmole) of BOC-NHCH(CO,CH,)CO-
NHcH(cH; )JCH=CHCH,CH(CH3), in 100 ml THF is treated with ‘3.5 g (30 mmole) of N-methylmorpholine-N-oxide and 100 mg (0.4 mmole) of osmium tetroxide is added. After stirring for 72 hours, the mixture is filtered and concentrated under \ reduced pressure. The residue is taken up in EtOAc and ! washed with 10% Na,SO,, 10% citric acid, saturated NaHCOj;, i . and saturated NaCl. Removal of the solvent under reduced pressure gives the crude product. The correct product is ‘ isolated by chromatography on silica gel. : H, NCH( CO, CH, )CO-CAD- HC1 . : A solution of 4.58 g (10 mmole) of BOC-NHCH(CO,CHj )CO- © CAD in 50 ml CHCl, is saturated with HCl gas and left stirring for two hours. The solvent is removed under reduced gS oO pressure, CH,Cl, is added and the solvent removed again. The o ~ crude product is thus obtained, sufficiently pure for use in g the next reaction. j
Lo.
Claims (1)
1. A process for the preparation of a peptide of i the formula A X-Y -W I or a pharmaceutically acceptable acid addilion salt thereof, wherein A is BOC, 1VA, BNMA, BMA, BB5P, £, R o - 0 i / LL web iu Ns \ / R' 4 . J ‘ wherein : 15 : R and R' are each independently hydrogen, straight or Po branched chain lower alkyl, Q N i153 a saturated ring containing 1 to 5 carbon nl TN / ip 20 atoms wherein ( is CHa, 0, 3, or NR: hy X is absent, PHE, HOMOPHE, NAPHTHYLALA, TYR or TYR ‘ (OMe) with the proviso that when A is BNMA or BBSP. X is absent. . : 3 Y is HH-CH-CO COz2R12 ] wherein R,> ios hydrogen, lower alkyl, alkenyl, alkynyl, or aralkyl; and W is a ~N NS i 110 OH wherein Rio is lower alkyl, cycloalkyl, cycloalkyl-methyl or benzyl and K,, is lower alkyl which comprises: bo N ’
. TTT e—————— A Heals vol a \ - 90 - : : : a) reacting an N-sul famyl amino acid with a : primary amine to form the corresponding sulfamyl benzyl methyl ester: b) reacting the N-sulfamyl benzyl methyl ester with hydrogen gas in Lhe presence of a catalyst to form the corresponding N-sulfamyl methyl ester acid; Cc) reacting the N-sulfamyl methyl "ester acid with the appropriate free amine to form the desired compound of formula I; and Co d) optionally hydrolyzing the methyl ester to ! ~~ 15 i} the free acid to form the desired compound of formula I. : RICHARD HIMMELSBACH : JOHN COOKE HODGES ] 20 JAMES STANLEY KALTENBRONN . ! WILLILAM CHESTER PATT \ JOSEPH THOMAS REPINE {LA SIRCAR i (Inventors) ; Co 25 NN A : : 30 i
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19999088A | 1988-05-27 | 1988-05-27 | |
US07/321,638 US5036053A (en) | 1988-05-27 | 1989-03-15 | Diol-containing renin inhibitors |
PH38698A PH26816A (en) | 1988-05-27 | 1989-05-25 | Diol-containing renin inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PH27036A true PH27036A (en) | 1993-02-01 |
Family
ID=27353997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH40714A PH27036A (en) | 1988-05-27 | 1990-06-21 | Process for the preparation of diol containing renin inhibitors |
Country Status (1)
Country | Link |
---|---|
PH (1) | PH27036A (en) |
-
1990
- 1990-06-21 PH PH40714A patent/PH27036A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU625456B2 (en) | Diol-containing renin inhibitors | |
US5063207A (en) | Renin inhibitors, method for using them, and compositions containing them | |
US5071837A (en) | Novel renin inhibiting peptides | |
US5036054A (en) | Renin inhibitors containing alpha-heteroatom amino acids | |
EP0315815A1 (en) | Branched backbone renin inhibitors | |
EP0434365A2 (en) | HIV protease inhibitors useful for the treatment of aids | |
EP0356223A2 (en) | HIV protease inhibitors useful for the treatment of aids | |
EP0202577A2 (en) | N(Acyldipeptidyl)-aminoglycols | |
CA1261332A (en) | Ester substituted aminoalkanoylureido amino and imino acid and ester compounds | |
US4895834A (en) | Renin inhibitors III | |
US4804743A (en) | Proline-containing renin inhibitors | |
US5643879A (en) | Amino-substituted heterocycles as renin inhibitors | |
US5221667A (en) | Renin inhibiting peptides having an α-heteroatom amino acid at the P3 position | |
US5198426A (en) | Renin inhibitors containing c-terminal dihydroxy amides | |
US4735933A (en) | Renin inhibitors III | |
US5219851A (en) | Tetrahydroisoquinoline-type renin inhibiting peptides | |
US5260278A (en) | Diol-containing renin inhibitors | |
PH27036A (en) | Process for the preparation of diol containing renin inhibitors | |
US5149692A (en) | Bisalkoxyphosphinyl compounds as renin inhibitors | |
EP0314060A2 (en) | Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them | |
US5162527A (en) | Renin inhibitors, processes for preparing them, methods for using them, and compositions containing them | |
EP0275480A2 (en) | Renin inhibitors IV | |
US5126451A (en) | Renin inhibitors containing α-heteroatom amino acids | |
EP0427939A2 (en) | Renin inhibitors | |
HU204070B (en) | Process for producing dipeptide derivatvies having renin inhibiting effect and pharmaceutical compositions comprising same |